Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Huang, Qianrui; Le, Yue; Li, Shusheng; Bian, Yi

doi:10.1186/s12931-024-02678-5

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Review
Open access
Published: 13 January 2024

Volume 25, article number 30, (2024)
Cite this article

Download PDF

You have full access to this open access article

Respiratory Research Aims and scope Submit manuscript

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Download PDF

Qianrui Huang^1,2^na1,
Yue Le³^na1,
Shusheng Li^1,2 &
…
Yi Bian^1,2

2861 Accesses
4 Citations
Explore all metrics

Abstract

Acute respiratory distress syndrome (ARDS) is a common condition associated with critically ill patients, characterized by bilateral chest radiographical opacities with refractory hypoxemia due to noncardiogenic pulmonary edema. Despite significant advances, the mortality of ARDS remains unacceptably high, and there are still no effective targeted pharmacotherapeutic agents. With the outbreak of coronavirus disease 19 worldwide, the mortality of ARDS has increased correspondingly. Comprehending the pathophysiology and the underlying molecular mechanisms of ARDS may thus be essential to developing effective therapeutic strategies and reducing mortality. To facilitate further understanding of its pathogenesis and exploring novel therapeutics, this review provides comprehensive information of ARDS from pathophysiology to molecular mechanisms and presents targeted therapeutics. We first describe the pathogenesis and pathophysiology of ARDS that involve dysregulated inflammation, alveolar-capillary barrier dysfunction, impaired alveolar fluid clearance and oxidative stress. Next, we summarize the molecular mechanisms and signaling pathways related to the above four aspects of ARDS pathophysiology, along with the latest research progress. Finally, we discuss the emerging therapeutic strategies that show exciting promise in ARDS, including several pharmacologic therapies, microRNA-based therapies and mesenchymal stromal cell therapies, highlighting the pathophysiological basis and the influences on signal transduction pathways for their use.

Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome

Article 04 September 2019

Mesenchymal Stromal Cell Therapy in Typical ARDS and Severe COVID-19

Acute Respiratory Distress Syndrome: Therapeutics, Pathobiology, and Prognosis

Background

Acute Respiratory Distress Syndrome (ARDS) is a clinical syndrome characterized by severe continuous hypoxemia, which can be caused by intrapulmonary and/or extrapulmonary causes. The most common cause is pneumonia, especially bacterial and viral pneumonia. In terms of extrapulmonary factors, sepsis due to non-pulmonary sources is the most common cause of ARDS. ARDS is mainly characterized by diffuse alveolar injury, including excessive inflammation, increased epithelial and vascular permeability, alveolar edema, and hyaline membrane formation. Although there are many pieces of research on the pathogenesis of ARDS, few specific pharmacotherapies for this disease can be used clinically [1]. Treatment of ARDS is generally supportive with lung-protective mechanical ventilation. Thus, the mortality of ARDS remains unacceptably high. The latest data from the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure study reports 40% hospital mortality of ARDS [2]. The outbreak of coronavirus disease 2019 (COVID-19) worldwide caused by severe acute respiratory syndrome coronavirus 2 has correspondingly increased the mortality of ARDS, leading to devastating economic and medical burden worldwide.

Recently, multiple studies have been published on the molecular mechanisms involved in pathogenesis and pathophysiology of ARDS and have made substantial progress. Some potential pharmacotherapeutic agents have proven efficacy in preclinical models of ARDS by targeting specific molecules or regulating related signal pathways. Considering the complex pathophysiology of ARDS characterized by inflammation-mediated disruptions in alveolar-capillary permeability, reduced alveolar fluid clearance (AFC), and oxidative stress, a comprehensive understanding of the underlying signal transduction within the pathogenesis and pathophysiology of ARDS significantly offers deep insight into development and progress of ARDS. This helps to provide a theoretical foundation and motivation for the discovery of novel therapeutic strategies to treat ARDS. In this review, we outline the available literature on mechanisms of pathophysiology and signal transduction for ARDS. Both novel and canonical signal transduction pathways are summarized and functionally classified according to their pathophysiological roles in ARDS, including inflammation, increased alveolar-capillary permeability, reduced AFC, and oxidative stress. We highlight these pathophysiological mechanisms by presenting the location and effects of the underlying signaling pathways in tissue, cells, and organelles. Furthermore, we introduce the recent findings of potential therapeutic strategies agents that target specific signaling pathways to modulate the above four aspects of pathophysiological mechanisms of ARDS.

Pathophysiology and pathogenesis of ARDS

The normal lung functions to facilitate oxygen transfer and carbon dioxide excretion, a process established by the alveolar–capillary unit. The pulmonary endothelium consists of a monolayer of endothelial cells linked by adherens junctions and tight junctions. It contributes significantly to the precise regulation of fluid and solutes to prevent lung flooding [3]. The alveolar epithelium is lined by alveolar type I cells, which form a tight barrier allowing gas exchange, and alveolar type II cells, responsible for producing surfactant to reduce surface tension and keep alveoli open. Both types of cells can absorb edema fluid from the alveolar space that help oedema resolution. The composition of the normal alveolus also includes alveolar macrophages (AMs), which provide host defense [4].

Regardless of the primary disease, the pathophysiologic manifestations of ARDS are very similar. Essentially, these syndromes reflect severe injury resulting in dysfunction of the alveolar-capillary barrier, impaired AFC, and oxidative injury due to unregulated acute inflammatory responses (Fig. 1).

Excessive inflammation

Acute lung injury (ALI) is initially caused by inflammation, which is mediated by an intricate interplay of inflammatory cytokines and chemokines released by various cell types in the lungs [5]. In response to direct insults such as bacteria, viruses and gastric contents, the pattern recognition receptors (PRRs) expressed in innate immune cells in alveolar, such as AMs, alveolar epithelial cells (AECs), and dendritic cells (DCs) are initially activated [6]. They release inflammatory cytokines to amplify immune response by acting locally on other cells and recruiting circulating immune cells into the airspace. This effect further induces amplification of inflammation and aggravates lung injury [7]. Neutrophils have been widely implicated in playing a critical role in the pathogenesis of ARDS. Activation of accumulated neutrophils in the alveolar space and lung microvasculature produces numerous cytotoxic substances, including granular enzymes, pro-inflammatory cytokines, and neutrophil extracellular traps (NETs), resulting in sustained inflammation and alveolar-capillary barrier injury [8]. Additionally, the influx of adaptive immune cells also plays an essential role in promoting inflammatory injury and thrombosis by producing various cytotoxic molecules such as cytokines, perforin, granzyme B, and autoantibodies [9,10,11].

Different from intrapulmonary ARDS, where alveolar inflammation occurs initially, inflammatory injury caused by indirect factors is driven from systemic compartment and spreads towards the alveolar compartment [12]. Lung endothelium activation, triggered by circulating stimuli released from extrapulmonary lesions into the blood, can also produce proinflammatory molecules to facilitate the adherence and infiltration of immune cells, further leading to vascular inflammation and alveolar damage [13].

Unlike other organs, the lung is continually exposed to various environmental challenges, including microbial pathogens, pollution, dust, and more [14]. Similarly, pulmonary endothelial cells are exposed to circulating inflammatory components, hormones, exotoxins, and endotoxins, which interact with both local and systemic inflammatory responses [15]. The alveolar epithelium, lung endothelium, and the cross-talk within the immune system collectively constitute the physical barrier and immune homeostasis in the lung [16]. Traditionally, a systemic inflammatory cascade has been used to describe immune dysregulation during ARDS, but this perspective has been challenged by the recognition of immune compartmentalization response [17]. It was previously observed that intratracheal administration of lipopolysaccharide (LPS) leads to a significant increase in tumor necrosis factor-α (TNF-α) levels in bronchoalveolar lavage fluid (BALF) but not in plasma, whereas intravenous LPS administration results in a potential increase in TNF-α levels in blood but not in BALF [14]. Recently, the compartmentalization of inflammation specific to the lung has also been observed in COVID-19-related ARDS [18]. Hence, when exploring biomarkers for diagnosis and subphenotyping, as well as investigating the pathophysiology and signaling pathways of ARDS, it is important to consider this organ-specific immune compartmentalization.

Endothelial and epithelial permeability

Another core pathophysiologic derangement is the increased permeability of two separate barriers, the lung endothelium and alveolar epithelium. As a result of dysregulated immune response, the impaired endothelial barrier can occur owing to disruption of intercellular junctions, endothelial cell death, and glycocalyx shedding. In normal lungs, maintenance of the endothelial barrier is mediated by vascular endothelial cadherin (VE-cadherin), which tightly connects adjacent endothelial cells, and prevents leucocyte migration and vascular leak [19, 20]. During lung injury, inflammatory factors mediate the phosphorylation of VE-cadherin, resulting in its endocytosis. Endocytosis of VE-cadherin induces gaps between endothelial cells, leading to increased permeability [21]. Moreover, the disruption of endothelial tight junctions, such as reduction in protein levels of occludins and zonula occludens (ZOs), can also promote intercellular permeability [22]. In addition, endothelial cell death can cause increased permeability to proteins and solutes [23].

Similar to endothelial injury, disruptions of epithelial barrier function involve the dissociation of intercellular junctions, primarily E-cadherin junctions, and alveolar epithelial cell death. In ARDS, various damaging factors can ruin the alveolar epithelium directly or by inducing inflammation. The inflammatory injury caused by immune response inevitably aggravates the direct damage to AECs, including cell death and intercellular junction disruption, leading to increased alveolar epithelial permeability [3].

Alveolar fluid clearance

The failure to absorb alveolar edema fluid significantly contributes to increased mortality in ARDS. Basal AFC is determined by ion and fluid transportation of alveolar epithelium. In normal epithelium, sodium is transported through the apical surface via the epithelial Na⁺ channel (ENaC) and then pumped from the basolateral surface into the lung interstitium by the sodium–potassium adenosine triphosphatase (Na,K-ATPase). while chloride is transported through the cystic fibrosis transmembrane conductance regulator (CFTR) channels [24]. The directional ion transport establishes an osmotic gradient that passively drives the removal of water from the alveoli to the interstitium through aquaporins or intracellular routes [25]. Subsequently, fluid can be eliminated via lymphatic drainage and lung microcirculation [4]. However, these transport systems and functions are impaired in ARDS patients due to epithelium injury caused by elevated levels of proinflammatory cytokines, leading to the loss of ion channels and pumps [26]. Increased permeability of liquid and protein into the alveolar space greatly exceeds the capability of AFC. The alveolar space filled with oedematose fluid decreases diffusion of carbon dioxide and oxygen, thus leading to hypoxia and hypercapnia and further impair AFC by inhibiting the Na,K-ATPase activity or inducing Na,K-ATPase endocytosis [27,28,29]. Patients with severe hypoxia frequently require mechanical ventilation to facilitate breathing. High tidal volumes and elevated airway pressures can induce biomechanical inflammatory injury and reduce Na,K-ATPase activity [30]. All of these events significantly inhibit AFC, leading to persistent alveolar edema, refractory hypoxemia and/or carbon dioxide retention.

Oxidative stress and lung injury

Oxidative stress, resulting from the production of reactive oxygen species (ROS), plays an important role in ARDS progression and lung injury. In response to inflammatory stimuli, various cell types in the lung can generate ROS. Most of the damaging ROS produced by innate immune cells like AMs and recruited leukocytes, cause cell injury by inducing oxidation and cross-linking of proteins, lipids, DNA, and carbohydrates [31]. Significantly, ROS produced by neutrophils disrupt the endothelial barrier, facilitating the migration of recruited inflammatory cells across it and thereby aggravating inflammation [32]. Similarly, activated AECs and pulmonary endothelial cells can produce ROS, directly contributing to signaling transduction that increases alveolar-capillary permeability and impairs sodium ion transport, thereby impairing the reabsorption of fluid from the alveolar compartment [33, 34]. In fact, oxidative stress and inflammatory response always reinforce each other in the progression of ARDS. Although there are many checks and balances in this system in the form of antioxidant defenses in ALI/ARDS, an excessive production of ROS overwhelms endogenous antioxidants, leading to oxidative cell injury and exacerbation of inflammatory responses [35].

Molecular mechanisms and signaling pathways

In this part, we discuss the specific functions of signaling pathways in regulating pathophysiological processes of ARDS including lung inflammation, alveolar-capillary permeability, and AFC, which contributes to discovering the potential and novel therapeutic strategies.

Signaling pathways related to inflammation

Pattern recognition receptors

The innate immune activation in both direct or indirect lung injury is considered a potent driver of lung inflammation. It is triggered by endogenous damage-associated molecular patterns (DAMPs) released by cells under conditions of stress, injury, or cellular death, as well as microbial-derived pathogen-associated molecular patterns (PAMPs). DAMPs and PAMPs can be recognized by PRRs expressed in host cells, initiating PRR-induced signaling pathways that lead to the expression of inflammatory factors. The following section mainly introduces the signaling pathways induced by PRRs, including toll-like receptors (TLRs), nucleotide-binding leucine-rich repeat receptors (NLRs), retinoic acid-inducible gene I (RIG-I) -like receptors (RLRs), cytoplasmic DNA sensors (CDSs), and receptors for advanced glycation end products (RAGEs) in relation to ARDS.

To date, 10 functional TLRs have been identified in humans. TLR1,2,4,5 and 6 are surface-expressed, while TLR3,7,8 and 9 are located in lysosomal or endosomal membranes. In the lung, different TLRs are expressed in various cell types and recognize specific PAMPs and DAMPs to generate inflammatory signals (Table 1) [6, 36]. The ability of TLRs to activate transcription factors interferon regulatory factors (IRFs) or nuclear factor-κB (NF-κB), requires the recruitment of adaptor proteins, including myeloid differentiation primary response gene 88 (MyD88) and Toll/interleukin-1 (IL-1) receptor-domain-containing adaptor-inducing interferon-β (TRIF). MyD88 is utilized by all TLRs except TLR3, and TRIF is specifically recruited by TLR3 [37]. Activation of IRFs and NF-κB triggered by TLRs are actively involved in the production of type I-interferons (IFNs) and pro-inflammatory cytokines, respectively (Fig. 2a). However, in the context of ARDS, TLR signals are accompanied by an overwhelming production of pro-inflammatory cytokines. Notably, TLRs elicit special responses in polymorphonuclear neutrophil granulocytes to aggravate inflammation during ARDS. Previous studies have revealed that TLR9 and TLR4 contribute to the release of NETs, which contain DAMPs of proteases, histones, and self-DNA to induce inflammation and thrombi development (Fig. 2d) [37,38,39,40]. A recent finding indicates that TLR9 activation induces neutrophil elastase and proteinase 3-mediated shedding of the complement component 5a receptor, resulting in a decreased ability to clear bacteria and prolonged ALI in mice [41]. Interestingly, the activation of TLR4 has been shown to play a dual role in regulating lung inflammation. TLR4 of AMs activated by heat shock protein (HSP) 70 conditionally promotes clearance of apoptotic neutrophils by preventing a disintegrin and metalloprotease 17 -mediated cleavage of Mer receptor tyrosine kinase, thereby promoting the outcome of ventilator-induced lung injury (VILI) [42]. Therefore, precise regulation of TLR signals to suppress inflammation and promote the resolution of ARDS may be an effective strategy.

Table 1 ARDS related PRRs and non-PRRs, their lung tissue distribution and recognition of PAMPs and DAMPs

Full size table

NLRs are also the commonly studied innate immune system receptors involved in ARDS. NLRs are cytoplasmic PRRs, which can be divided into different subfamilies according to their N-terminal domains, including nucleotide-binding oligomerization domain (NOD), nucleotide-binding domain leucine-rich repeat protein (NLRP), neuronal apoptosis inhibitory protein (NAIP), and nucleotide-binding oligomerization domain like receptor subfamily C (NLRC) [6, 43]. The NOD1 and NOD2 mainly detect bacterial components, recruiting downstream receptor-interacting-serine/threonine-protein kinase 2, which leads to NF-κB or mitogen-activated protein kinase (MAPK) activation [36]. The NLRP1, NLRP3, NLRC4 and NAIP have been characterized to assemble inflammasomes in the lung (Table 1) [6]. In general, the activation of the inflammasome requires two independent signals. The priming signal is the upregulation of NLRs, pro-IL-1β, pro-IL-18, and pro-caspase-1 through NF-κB activation. The second step is induced by NLRs responding to a variety of PAMPs and DAMPs inside the cell (Table 1) [44]. The activated NLRs further assemble inflammasomes to mediate caspase-1-dependent cleavage of pro-IL-1β and pro-IL-18. The secretion of mature forms of IL-1β and IL-18 can further induce inflammation by recognizing their respective cytokine receptors to trigger MyD88/NF-κB signaling [45]. In addition, inflammasome activation can induce cell pyroptosis through caspase-1-mediated proteolysis of gasdermin D, resulting in the formation of pores on the cell membrane and subsequent cell rupture [46]. Pyroptosis leads to a large release of DAMPs and inflammatory mediators (incl. IL-1β and IL-18) that enhances further inflammatory responses [45]. The synergistic interaction between NF-κB and NLRs may account for the supranormal release of cytokines. Thus, inhibition of NF-κB signal and targeting NLRs appear to hold potential for mitigating inflammasome-induced ARDS and the subsequent cytokine storm.

The surveillance of abnormal nucleic acids from invading pathogens or damaged cells is conducted by PRRs including RIG-I, melanoma differentiation-associated gene 5 (MDA5), cyclic GMP-AMP synthase (cGAS), and absent in melanoma 2 (AIM2). Both the cytosolic receptor RIG-I and MDA5 expressed in various host cells belong to RLRs, which provide important defense against viral infections (Table 1) [47, 48]. They recognize viral RNA containing a 5′-triphosphate end and subsequently activate the downstream adapter mitochondrial antiviral signaling protein (MAVS) to induce the activation of IRFs and NF-κB (Fig. 2c) [49]. These signals result in the expression of antiviral type I-IFNs and other inflammatory cytokines [50]. However, there is evidence that RLR signaling cascades induce excess inflammation in ARDS, clinically manifested by upregulation of inflammatory cytokines in the bronchoalveolar lavage fluid of patients with severe viral infections [51].

The abnormal presence of DNA in cytoplasm either from infection or cellular damage induces immune responses through the cytoplasmic DNA sensors, including cGAS and AIM2 (Table 1). cGAS binds to double-stranded DNA, driving the synthesis of cyclic dinucleotide cyclic GMP-AMP (cGAMP), which activates the stimulator of the interferon gene (STING), an endoplasmic reticulum (ER) membrane protein. Activated STING induces the production of inflammatory factors through the activation of downstream NF-κB and IRF 3 (Fig. 2b) [52]. AIM2 detects double-stranded DNA to assemble an AIM2 inflammasome complex, which contains AIM2, apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1. This complex regulates the maturation of IL-1β and IL-18, as well as induces cell pyroptosis [43, 53]. Similarly, sustained activation of these pathways is detrimental to the host. For instance, self-DNA released by cell death or cellular stress after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may activate the cGAS-STING pathway, leading to excessive production of inflammatory factors and exacerbating the severity of COVID-19 [52]. Of note, the cGAS-STING signaling pathway has been shown to phosphorylate the signal transducer and activator of transcription (STAT) 1, which results in the production of adhesion molecules and chemokines to promote immune cell adhesion and migration during ARDS in vivo [54]. Thus, targeting signaling pathways associated with nucleic acid sensors offers potential avenues for anti-inflammatory therapy in ARDS.

RAGE is a PRR highly expressed in the lungs, particularly in AECs (Table 1) [55]. It exists in two forms: membrane-bound and soluble. Membrane-bound RAGE can recognize a variety of ligands (Table 1), triggering various intracellular cascades including NF-κB, MAPK, and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), ultimately leading to the induction of inflammatory factors (Fig. 2a) [56]. Since the expression of RAGE is significantly upregulated during ARDS, persistent inflammation from RAGE activation may induce harmful effects [57]. In contrast, soluble RAGE is thought to be protective, as it retains the ability of ligand binding while lacking signaling function [58]. Together, targeting membrane-bound RAGE to inhibit inflammatory signaling pathways or competitive binding RAGE ligands through the administration of soluble RAGE could be a therapeutic strategy for ARDS.

In addition to PRRs, there are other receptors that serve as positive regulators of inflammation by recognizing various DAMPs or PAMPs (Table 1). The purinergic ionotropic receptors P2X7 are membrane ion channels involved in the activation of NLRP3 inflammasomes by recognizing extracellular ATP (Fig. 2a) [59, 60]. The transient receptor potential (TRP) channels on the cell surface allow Ca²⁺ influx to initiate the NF-κB-dependent inflammatory responses, which can be triggered by environmental irritants such as inflammatory cytokines and pathogens [61,62,63]. The N-formyl peptide receptor (FPR) is a member of G-protein-coupled receptors (GPCRs). It recognizes N-formylated peptides derived from bacterial or mitochondria, activating downstream MAPKs, AKT, and NF-κB pathways to induce inflammation [64]. Activation of neutrophils in response to the FPR signal leads to inflammatory responses, such as elastase release, oxidative burst, and chemotactic migration (Fig. 2d) [65]. The activation of these signaling pathways significantly contributes to the development of robust inflammatory responses during ARDS. Conversely, adenosine receptors, which also belong to GPCRs, have been reported for their advantageous anti-inflammatory effects in ARDS. Notably, there is an essential link between hypoxia and inflammatory signaling, serving as a vital physiological protective mechanism to alleviate acute lung inflammation [66]. Mechanistically, cytoplasmic hypoxia-inducible factors (HIFs) stabilize in response to hypoxia and translocate to the nucleus to induce the transcription of adenosine receptors. Besides, the increased release of extracellular ATP/ADP during inflammation also raises the adenosine levels, which promotes a feedback loop that attenuates inflammation [67, 68]. A subtype of adenosine receptors, the A2A receptor, has been identified as the target gene of HIF-1α in alveolar epithelium contributes to lung protection during ALI [69]. In addition, Ko et al. found that A2A receptor exerts anti-inflammatory functions by inhibiting downstream MAPK and NF-κB [70]. However, the physiological protecting HIF/adenosine signaling is often compromised in ARDS patients due to the necessity of hyperoxic conditions in the lung, which may exacerbate acute inflammatory lung injury [71].

NF-κB signaling pathway

NF-κB is a transcription factor named for its specific binding to a conserved sequence in the nuclei of activated B lymphocytes [72]. In a resting state, NF-κB exhibits no transcriptional activity as it binds to the NF-κB inhibitor (IκB) in the cytoplasm. Upon activation of the IκB kinase by upstream signals, it induces the dissociation and subsequent degradation of IκB protein from NF-κB. Consequently, NF-κB translocates to specific DNA target sites in the nucleus, initiating the transcription and expression of inflammatory genes [73]. The NF-κB signal can be triggered by multiple stimuli, including cytokines (e.g., TNF-α and IL-1β), microbial infection (LPS), activated PRRs as described above, stress (e.g., ER stress and ROS), as well as elevated CO₂ during hypercapnia [74, 75]. Notably, aberrant regulation of NF-κB is implicated to induce detrimental inflammation in ARDS [76]. The NF-κB pathway produces a variety of cytokines, chemokines and adhesion molecules, contributing to processes encompassing inflammation, immune cell recruitment, cell adhesion and cell differentiation. For instance, after the exposure of the lungs to noxious agents, NF-κB activation can be initiated by PRRs in both epithelial and endothelial cells, as well as resident immune cells, primarily AMs. Subsequently, these activated cells release cytokines (such as TNF-α and IL-1β) and chemokines (such as IL-8 and monocyte chemoattractant protein-1), amplifying inflammation by activating adjacent cells and recruiting additional immune cells from the peripheral tissues [74]. NF-κB activation also promotes AM polarization into classically activated (M1) macrophages, which overproduce cytokines to drive cytokine storm [77]. In the endothelium, activated NF-κB triggers the expression of adhesion molecules, which promotes the recruited immune cells to adhere and cross the alveolar-capillary barrier to reach the alveolar space, where they propagate inflammation and injury through the production of sustained inflammatory cytokines [78]. Besides, NF-κB can downregulate the anticoagulation proteins to cause intravascular coagulation and thrombin generation, which in turn aggravates inflammatory lung injury [79]. All of these events together contribute to the progression of ARDS. Therefore, modulating the activation of NF-κB and inhibiting the degradation of IκB hold potential for mitigating the cytokine storm and ameliorating the severity of ARDS.

Notch signaling pathway

The Notch signaling pathway is well-studied for regulating cell proliferation and differentiation in respiratory system [80]. Currently, four Notch receptors (Notch 1, 2, 3, and 4) and five ligands (Jagged-1, 2 and delta-like ligand 1, 3, and 4) have been identified in mammals. Upon activation, the Notch intracellular domain is released and translocates to the nucleus, where it activates the transcription of target genes such as Hairy/Enhancer of Split 1 (Hes1) [81]. Several studies have highlighted the significant role of the Notch pathway in sepsis and ARDS, particularly in promoting proinflammatory cell polarization. Notch activation in macrophages drives M1 polarization to induce inflammation, whereas the inactivation of Notch signaling typically contributes to alternatively activated (M2) macrophage polarization that alleviates inflammation [82, 83]. Li et al. [84] reported that Notch signaling is involved in T helper 17 (Th17) cell differentiation, which releases IL-17 and IL-22 to aggravate lung inflammation and neutrophil infiltration in an LPS-induced ALI model. Conversely, some research have also suggested a role for Notch signaling in anti-inflammatory responses. Lu et al. [85] found that mesenchymal stem cells activate Notch signaling, leading to the production of regulatory DCs, which inhibit inflammatory responses against LPS-induced ALI. Whether this signaling pathway facilitates or inhibits ARDS remains inconclusive.

Janus kinase (JAK)/STAT signaling pathway

The essential role of the JAK/STAT signaling pathway in apoptosis, differentiation, and inflammation is widely studied. The JAK family consists of four members (JAK1, 2, 3, and tyrosine kinase 2), while the STAT family comprises seven members (STAT1, 2, 3, 4, 5A, 5B, and STAT6) [86]. This pathway functions by transmitting extracellular signals from cytokines or growth factors to the nucleus, triggering the transcription of target genes [87]. JAK/STAT mediated by cytokines plays a critical role in amplifying inflammatory signals. For example, JAK/STAT pathway can amplify inflammation both in immune and non-immune cells. The activation of JAK/STAT3 by IL-6 promotes the differentiation of Th17 cells, CD8⁺ T cells, and B cells while inhibiting the development of regulatory T cells [88]. Type II-IFN-mediated JAK/STAT1 activation induces pro-inflammatory M1 phenotypes (Fig. 2c) [89]. STAT1, STAT3 and STAT5, when activated by granulocyte colony-stimulating factor (G-CSF) promote the accumulation and activation of neutrophils in the lung (Fig. 2d) [90]. Excessive activation of these immune cells leads to an unrestrained release of pro-inflammatory cytokines and chemokines, aggravating lung injury [91]. In non-immune cells, such as pulmonary endothelial cells and AECs, the IL-6/JAK/STAT3 axis induces the releasing of various inflammatory cytokines and chemokines, significantly associated with the severity of ARDS (Fig. 2b) [92].

Moreover, JAK/STAT is implicated in the differentiation of anti-inflammatory immune cells, suggesting its potential effect for relieving the inflammatory reaction on ARDS. IL-4 and IL-2 participate in Th2 differentiation, leading to the release of anti-inflammatory cytokines that counteract Th1 cells through the activation of STAT6 and STAT5, respectively [91, 93]. Activation of JAK/STAT6 triggered by Th2-related cytokines such as IL-4 and IL-13, along with the JAK1/STAT3 signaling triggered by IL-10, may promote M2 polarization. This polarization is pivotal in inflammatory resolution and lung fibroproliferative response in the late phase of ALI/ARDS (Fig. 2c) [89, 94].

Here, the function of JAK/STAT pathway is precisely controlled by diverse inflammatory cytokines. Modulating the effects of downstream JAK/STAT pathway by targeting pro-inflammatory cytokines or/and their respective receptors may have therapeutic efficacy in ARDS.

MAPK signaling pathway

The MAPKs are a class of serine/threonine protein kinases in cells that transmit signals through a three-tiered sequential phosphorylation cascade and induce various cellular responses [55]. MAPKs are subdivided into four distinct subfamilies, namely extracellular signal-regulated kinase (ERK) 1 and ERK2, c-Jun N-terminal kinase (JNK), p38MAPK, and ERK5 [95]. The activation of MAPK pathway can be initiated by multiple stimuli, such as growth factors and cytokines, through their interaction with specific receptors. Additionally, environmental stress and infections can directly trigger MAPK activation [96]. Recent studies have underscored the pivotal role of the MAPK pathway in the inflammatory processes in ARDS, primarily through the facilitation of the release of inflammatory cytokines and chemokines [97,98,99]. Besides, accumulating evidence have demonstrated that MAPK activation aggravates lung inflammation of ARDS by upregulating the activity of NLRP3 inflammasome and NF-κB in animal models [100,101,102]. In addition, previous studies have revealed the involvement of the MAPK pathway in eliciting tissue factor expression in endothelial cells under inflammatory stimuli such as TNF-α and C-reactive protein, which results in activating the coagulation system and fibrin deposition (Fig. 2b) [103,104,105]. Thus, blocking the MAPK signaling may reduce lung damage from ARDS by alleviating inflammatory response and the clotting cascade.

PI3K/AKT signaling pathway

The PI3K/AKT pathway is ubiquitous in cells and participates in numerous pathophysiological processes of ARDS [106]. Cell surface receptor tyrosine kinases and GPCRs recognize their ligands, activating PI3K, which in turn converts phosphatidylinositol 4,5-bisphosphate into phosphatidylinositol 3,4,5-trisphosphate to activate AKT [107]. The role of the PI3K/AKT pathway in regulating inflammation during ARDS remains controversial. Zhong et al. [108] recently reported that the mammalian target of the rapamycin (mTOR), a downstream target of PI3K/AKT, phosphorylates the downstream transcription factor HIF-1α to induce a glucose metabolic reprogramming of macrophages, resulting in NLRP3 inflammasome activation and aggravate macrophage-mediated inflammation in LPS-induced ALI model. Besides, several studies have shown that the activation of the PI3K/AKT pathway increases inflammatory cytokines by activating the downstream NF-κB signal [109,110,111]. However, some recent studies have drawn a different conclusion, suggesting that the activation of PI3K/AKT is related with the alleviation of lung inflammation [112, 113]. Zhong et al. [113] reported that PI3K/AKT activation inhibited downstream NF-κB and NLRP3 inflammasome to alleviate inflammation in LPS-induced ALI model. Therefore, further investigation is necessary to explore the potential positive and/or negative effects of PI3K/AKT pathway in regulating inflammation in ARDS.

ER stress-mediated signaling pathway

Various pathological conditions, such as sepsis, trauma, ischemia, and viral infections, can induce ER stress, defined as the accumulation of unfolded or misfolded proteins in the ER lumen [114]. Protein kinase RNA-like ER kinase (PERK), inositol requiring kinase 1α (IRE1α), and activating transcription factor 6 (ATF6) are transmembrane proteins of ER. They transduce ER stress signals induced by cellular homeostasis imbalances, initiating the unfolded protein response, which protects the cell by degrading these unfolded or misfolded proteins [115]. However, severe or prolonged ER stress has been observed to promote inflammation in ARDS by activating a series of signals, such as MAPK and NF-κB [116,117,118]. Ye et al. [119] reported that the phosphorylated IRE1α during mechanical ventilation activates NF-κB signaling to promote lung injury and inflammatory processes (Fig. 2b). Given its role in the inflammatory cascade, pharmacological interventions targeting ER stress might be a potential strategy for ARDS therapy.

Transforming growth factor-β (TGF-β)/Small mothers against decapentaplegic (Smad) signaling pathway

The TGF-β signaling pathway is well accepted to induce lung fibrosis resulting from various diseases [120]. The interaction between TGF-β and its membrane TGF-β receptor complex leads to the phosphorylation of cytoplasmic effectors Smad2/3, forming a complex with Smad4 that translocates into the nucleus to regulate gene expression [121]. It was shown earlier that the TGF-β pathway contributes to the development of ARDS through the promotion of lung permeability, impaired epithelial ion transport, and fibrosis [34, 122, 123]. In addition, TGF-β exhibits potent proinflammatory properties. As early as 1994, Shenkar et al. [124] showed that mice administered anti-TGF-β antibodies exhibited reduced pro-inflammatory cytokine levels in comparison to untreated mice in a hemorrhage-induced ALI model. Similarly, a recent study demonstrated a reduction in inflammatory cytokine levels in an ALI model after inhibiting TGF-β/Smad signaling in vitro [125]. Another proinflammatory mechanism is that TGF-β activates MAPK and NF-κB in a Smad-independent pathway, which can occur in M1 phenotype transformation to induce inflammation (Fig. 2c) [89, 126]. In summary, active TGF-β signaling plays a critical role in ARDS, making it a potential therapeutic target.

TNF-α signaling pathway

TNF-α is a key cytokine involved in initiating and perpetuating inflammation in ARDS, produced by various cells in response to inflammatory stimuli [127]. TNF exerts its cellular effects through two cell surface receptors, TNF-receptor (TNFR) 1 and TNFR2. Binding of TNF-α to TNFR1 recruits adaptor proteins, including TNFR-associated death domain (TRADD) protein and TNFR–associated factor (TRAF) 2, activating NF-κB, MAPK, and activator protein-1 (AP-1) (Fig. 2b). These activated signals subsequently increase the expression of TNF-α to amplify the inflammatory effects [128]. The recent documentation of TNF-α's proinflammatory role in animal models of ALI/ARDS induced by LPS and severe acute pancreatitis suggests that targeting TNF-α could be an attractive therapeutic approach for ARDS [127, 129, 130].

Increased endothelium and epithelium permeability

Emerging evidence has suggested that different modalities of cell death, such as necrosis, apoptosis, necroptosis, ferroptosis, and pyroptosis, coexist in the endothelium and epithelium of lung during ARDS, leading to barrier dysfunction and pulmonary edema. Besides, the disruption of intercellular junctions and cytoskeleton reorganization is required for the loss of alveolar-capillary barrier integrity. These events ultimately lead to the accumulation of leaking fluid and proteins in alveolar spaces.

Alveolar epithelial and pulmonary endothelial cell death

Apoptosis has been widely demonstrated to cause the injury of endothelium and epithelium in the lung during ARDS. This programmed type of cell death can be triggered by extrinsic or intrinsic apoptosis pathways. Several well-studied signaling pathways led by death receptors have been implicated to mediate extrinsic apoptosis, which includes the Fas/Fas ligand (FasL), TNF-α/TNFR1 and TNF-related apoptosis-inducing ligand (TRAIL)/TNF-related apoptosis-inducing ligand receptor (TRAILR) [131]. Many studies have supported the significant role of Fas/FasL signaling in epithelial apoptosis in ARDS, with elevated concentrations of Fas and FasL detected in the BALF of ARDS patients [132]. In vitro experiments demonstrated that BALF from ARDS patients induced apoptosis in a lung epithelial cell line, which could be reversed by blocking Fas/FasL signaling [133]. Besides, multiple animal studies have pointed out the role of Fas/FasL in inducing AEC apoptosis and lung edema during ALI/ARDS [134,135,136]. In addition, TNF-α/TNFR1-mediated apoptosis may contribute to endothelial injury in ARDS. Hamacher et al. [137] demonstrated that BALF from ARDS patients exhibited cytotoxicity towards human lung microvascular endothelial cells. This cytotoxic activity was effectively inhibited by neutralizing TNF-α antibodies. Contradictory findings regarding the role of TNF-α/TNFR1 in mediating alveolar epithelial apoptosis have complicated the understanding of ARDS. A previous in vivo study demonstrated that intratracheal TNF-α instillation did not dramatically affect the early apoptotic cell death in lung after LPS exposure [138]. While Sun et al. [139] recently found that TNF-α significantly enhances IFN-β-mediated apoptosis of airway epithelial cells in vitro. The involvement of TRAIL/TRAILR signaling in apoptosis and lung barrier dysfunction during ARDS has also been described [140]. Previous reports have identified type I-IFNs as potent inducers of TRAIL in AMs. The substantial release of TRAIL from AMs upon type I-IFN stimulation may lead to apoptosis in alveolar epithelium [141]. ARDS is also associated with the intrinsic apoptosis, which occurs due to increased permeability of the mitochondrial outer membrane, known as mitochondrial-dependent apoptosis. This form of apoptosis can be induced by various stimuli, such as elastase, ROS and LPS [33, 142]. Additionally, dynamin-related protein 1 (Drp1), a cytoplasmatic GTPases, has been proven to trigger mitochondrial-dependent apoptosis by inducing mitochondrial fission in AECs recently [143, 144]. In addition to the extrinsic or intrinsic apoptosis pathways, several other signaling pathways play a role in regulating apoptosis in ARDS. Apoptosis signal-regulating kinase 1 (ASK1), a member of MAPK kinase kinase kinase family, is ubiquitously expressed in various cell types. When the cells are exposed to inflammatory factors, ASK1 becomes activated to phosphorylate JNK and further induces cell apoptosis [145]. ASK1/JNK-mediated apoptosis in alveolar epithelium and endothelium has already been reported in various ALI models [145,146,147]. In contrast, the PI3K/AKT pathway exerts a protective role in resisting apoptosis by inactivating proapoptotic proteins, with its activation partially dependent on the binding to vascular endothelial growth factor (VEGF) [142, 148]. However, this protective pathway is downregulated during ARDS, partially attributed to decreased VEGF expression in injured epithelial cells, leading to aggravating alveolar-capillary injury [149, 150].

Necroptosis is another cell-destruction procedure that has been implicated in inducing endothelial/epithelial injury in ARDS. Necroptosis is initiated by various receptors (e.g., Fas, TNFR, TLRs), inflammatory cytokines and mitochondrial dysfunction. Subsequently, receptor-interacting protein kinase (RIPK) 1 and/or RIPK3 are recruited, leading to the activation of mixed lineage kinase domain-like protein (MLKL), which damages cell membrane integrity and induces necroptosis [151, 152]. Various ALI/ARDS preclinical models have recently demonstrated evidence of necroptosis in epithelial and/or endothelial barrier dysfunction, as assessed by RIPK and MLKL measurements [153,154,155,156]. Besides, a large ICU cohort study has implicated RIPK3 in the development of VILI. Subsequent animal experiments have indicated the importance of necroptotic function of RIPK3, evident in the protective effect observed in RIPK3 knockout mice, whereas MLKL knockout mice remained unaffected by VILI [157]. Moreover, lung autopsy of COVID-19 ARDS patients has found that angiopoietin (Ang) 2 levels are correlated with necrotic lung endothelial cell death, as shown by a linear correlation between levels of Ang2 and RIPK3 [158]. Based on these studies, the use of inhibitors targeting the necroptosis pathways involving RIPK and MLKL shows promise as a potential therapy for ARDS.

Autophagy, a catabolic process that degrades cytoplasmic components to maintain cell homeostasis, can have either beneficial or injurious effects in response to different stimuli [159]. While autophagy is an adaptive process, excessive autophagy can lead to cell death. Nonetheless, there is a paradoxical role of autophagy in mediating alveolar-capillary barrier function in ARDS. In previous research, H5N1 infection induced autophagy of AEC via inhibition of PI3K/AKT/mTOR1 pathway [160]. Besides, exposure to LPS was reported to induce autophagic death in human alveolar epithelial cell death via the activation of the PERK pathway upon ER stress in vitro [161]. However, a recent study suggests that LPS-induced autophagy decreases cell death in mouse lung epithelium [162]. These discrepant findings may be attributed to variations in experimental conditions, highlighting the intricate role of autophagy in the pathogenesis of ARDS. Thus, there is still high research value on the effect of autophagy in this field.

Differing from other forms of cell death, pyroptosis is an inflammatory programmed cell death induced by various pathological stimuli or microbial infections, accompanied by release of inflammatory cytokines [163]. The pyroptotic pathway comprises the canonical pathway, which is mediated by caspase-1 and relies on inflammasome activation, as well as the non-canonical pathway associated with caspase-4/5/11. The formation of canonical inflammasomes primarily involves cytoplasmic sensors, with NLRs and AIM2 being the most common [164]. Numerous studies have indicated that pyroptosis of epithelial and endothelial cells mediated by PAMPs and DAMPs could lead to increased barrier permeability and amplification of inflammatory cascade [165,166,167]. Thus, we suggest that modulating specific elements within the pyroptotic pathways of epithelial and endothelial cells could potentially mitigate the development of ARDS, preserving alveolar-capillary integrity and attenuating the secretion of cytokines.

Intercellular junction impairment of epithelium and endothelium

The normal endothelium forms connections through intracellular tight junctions (TJs) and adherens junctions (AJs). TJs consist of transmembrane proteins, including claudins, occludins and junctional adhesion molecules (JAMs), as well as cytoplasmic ZO proteins responsible for anchoring tight junctions to actin cytoskeleton [168]. VE-cadherin serves as the primary component of AJs and establishes connections with p120 catenin, β-catenin, and α-catenin to link with the actin cytoskeleton. The stabilization of VE-cadherin is achieved through the receptor tyrosine kinase Tie2 and vascular endothelial protein tyrosine phosphatase (VE-PTP), both of which prevent its internalization and thus protect against endothelial barrier disruption [4]. The intracellular structure of alveolar epithelium is similar to endothelium, but its main component of AJs is E-cadherin. The coordinate expression and interplay of AJs, TJs and the actin cytoskeleton play a key effect in maintaining the alveolar-capillary barrier integrity.

Multiple signaling pathways have been found to downregulate the integrity of epithelial and endothelial barriers during ARDS, some of which are associated with reduced expression and distribution of AJs proteins. Xiong et al. [169] found that the disruption of the endothelial barrier by IL-1β was attributed to the downregulation of the transcription factor cyclic adenosine monophosphate (cAMP) response element binding (CREB), along with its target VE-cadherin (Fig. 3). Besides, the internalization of VE-cadherin may also lead to endothelial barrier disruption through the separation between intercellular VE-cadherin bonding. Research has provided evidence that TLR4 activation triggers Src kinase phosphorylation, subsequently leading to the phosphorylation of p120-catenin and VE-cadherin. This results in VE-cadherin internalization and increased paracellular permeability in sepsis-induced ALI model (Fig. 3) [170].

Likewise, decreased expression of TJs proteins may contribute to barrier disruption. It has been reported that Drp1-meditated mitochondria fission could induce deregulation of ZO-1 and occludins on ALI models [143]. Significantly, the interaction of RAGE and high-mobility group box 1 (HMGB1) plays a crucial role in the dysregulation of both TJs and AJs during ARDS. Studies have indicated that the HMGB1/RAGE signaling pathway downregulates the expression of VE-cadherin and E-cadherin in endothelium and epithelium, respectively, paralleled with decreased expression of TJs proteins such as occludins, claudins and ZO-1 in preclinical ARDS models (Fig. 3) [67, 171].

In addition, barrier hyperpermeability is also related to the cytoskeleton rearrangement in epithelium and endothelium, which induces actin cytoskeleton shortening, cell contraction and intercellular junction rupture [172]. The intracellular Rho GTPase family, RhoA, Rac and Cdc42, play pivotal roles as regulators of cytoskeletal rearrangement [173]. Rac1 and RhoA exhibit opposing effects: Rac1 facilitates the assembly and maintenance of AJs, whereas RhoA induces cytoskeletal contraction through the activation of Rho-associated protein kinase (ROCK) and subsequent myosin light chain (MLC) phosphorylation [174, 175]. Various inflammatory agents, such as IL-1, TGF-β, thrombin, endothelin-1 and angiotensin II, have been shown to activate the RhoA/ROCK signaling in the pathogenesis of ARDS [174]. Besides, some molecular pathways also participate in regulating RhoA/ROCK signaling. Sphingosine-1 phosphate (S1P) released by activated platelets can recognize its receptors S1P2 and S1P3 on the surface of endothelial cells, thereby inducing RhoA/ROCK-dependent barrier disruption (Fig. 3) [173]. HMGB1/RAGE has been previously studied to induce cytoskeleton rearrangement through downstream activation of p38MAPK and phosphorylation of actin-binding protein HSP27. Recently, it has been reported to activate downstream RhoA/ROCK to enhance alveolar-capillary permeability [171]. Ca²⁺ influx triggered by the activation of transient receptor potential‑vanilloid 1 channels has been reported to induce cytoskeleton rearrangement in alveolar epithelium of seawater inhalation-induced ALI model, but whether RhoA/ROCK is involved has not been elucidated (Fig. 3) [62].

Moreover, the epithelial–mesenchymal transition (EMT) is considered a pivotal phenomenon during the progression of ARDS. During this process, an epithelial cell line loses its epithelial morphology and gains mesenchymal morphology, as manifested by the downregulation of intracellular junction proteins along with the expression of profibrotic proteins such as α-smooth muscle actin. Studies have demonstrated the activation of the Wnt/β-catenin pathway in ALI/ARDS. Wnt protein released by macrophages combines to its receptor Frizzled on the membrane of alveolar epithelium, resulting in β-catenin translocation to the nucleus and subsequent regulation of various genes. This process ultimately promotes EMT and induce pulmonary fibrosis [176,177,178]. Interestingly, recent reports have indicated that Wnt signaling upregulated by mesenchymal cells under hypercapnia condition impairs the proliferative capacity of alveolar epithelial cells by inhibiting downstream β-catenin signaling, leading to epithelial barrier dysfunction and exacerbates pulmonary edema [179]. Thus, modulating this pathway could serve as a therapeutic strategy to alleviate fibrosis and promote lung repair after injury.

Several signaling pathways exert barrier protective functions in lung tissue, although they are generally downregulated during ARDS. Many molecular pathways within the endothelium collaborate to enhance barrier function through the stabilization and increased expression of VE-cadherin. The Ang-Tie2 signaling axis has been extensively studied as one of the pathways implicated in inducing endothelial barrier dysfunction during inflammatory diseases like sepsis and ARDS [180]. Both Ang1 and Ang2 are ligands of Tie2 but exert an opposite role in this signaling pathway by competitive binding Tie2. Activation of Tie2 by Ang1 leads to the inhibition of Src kinase, preventing the internalization of VE-cadherin [181]. Besides, the Ang1/Tie2 signaling also activates downstream PI3K/AKT to activate Rac1 kinase, leading to prevent cytoskeleton rearrangement (Fig. 3) [182]. Nevertheless, the elevated levels of Ang2 during ARDS hinder these vascular protective effects of Tie2 activation [183].

Additionally, the upregulation of Tie2 expression can provide additional protection for vascular barrier integrity by preventing the disruption of VE-cadherin junctions. In a recent study, the protective role of endogenous bone morphogenetic protein 9 (BMP9) has been demonstrated in a murine ALI model. Exogenously applied BMP9 binds to its receptor, activin receptor-like kinase 1 (ALK1) exclusively expressed in endothelial cells, leading to increase Tie expression and preventing further VE-cadherin internalization (Fig. 3). However, the protective effect of BMP9 for barrier integrity is diminished due to the cleavage of BMP9 by neutrophil-derived proteases during ARDS [184]. The Roundabout 4 (Robo4) is an endothelial-specific receptor, which prevents VE-cadherin internalization via interacting with the endothelium-derived ligand Slit2 to suppress vascular permeability (Fig. 3) [185]. Exogenously applied Slit2 N-terminal fragment has previously been demonstrated to protect mice against vascular leakage in the lung exposed to various conditions [186]. However, a recent study by Morita et al. [187] revealed that BMP9/ALK1 signaling negatively regulates the Robo4 expression. In their studies, inhibition of ALK1 in mouse COVID-19 models was found to upregulate Robo4 expression and suppress vascular permeability in the lung. Further studies are required to investigate the interaction between BMP9/ALK1 and Robo4 signaling and their exact role in ARDS.

Hypoxemia, a hallmark of ARDS in patients, has previously been implicated in the activation of HIF-2α, leading to increased VE-PTP gene expression and enhancement of the adhesive function of VE-cadherin (Fig. 3) [188]. Controlling this endogenous protective mechanism properly may be of value in patients with ARDS.

Moreover, epithelial regeneration following ARDS is recognized as crucial for improving respiratory function in the remaining lung. Recently, the Hippo/yes-associated protein (YAP) pathway has emerged as a contributor to lung repair and recovery after ALI. In the late phase of ARDS, the key effector molecule YAP transfers from the cytoplasm into nucleus to govern the expression of target genes, promoting AT II proliferation and the reassembly of epithelial AJs (Fig. 3) [189, 190].

Impaired alveolar fluid clearance

It is well recognized that the active fluid transport is impaired in ARDS, which is associated with increased permeability of alveolar-capillary integrity and impaired AFC controlled predominately by ENaC, Na,K-ATPase, CFTR channels and aquaporins. Here we focus on the signaling pathways that mediate ion and water transport across the lung epithelium during ARDS.

Previous studies have shown that elevated levels of proinflammatory factors during ARDS resulted in reduced expression of alveolar ion channels and impaired AFC. For example, IL-1β and LPS reportedly reduce the expression of ENaC via p38MAPK activation to decrease AFC [191, 192]. TNF-α induces declines in ENaC activity and expression through binding to TNFR1 [193]. TGF-β/Smad signaling decreases ENaC and CFTR expression, resulting in AFC failure [34, 194]. Elevated levels of angiotensin II after lung injury have been implicated to decrease ENaC expression through the inhibition of cAMP [195]. Besides, it has been suggested that TRAIL/TRAILR signaling induces the degradation of Na,K-ATPase independent of cell death pathway elicited by caspases, mediated by the cytoplasmic AMP-activated protein kinase (AMPK) [196]. Moreover, the expression of aquaporins has been shown to be downregulated through RAGE signaling and p38MAPK activation [197]. These signaling pathways strongly reveal a cross-link between inflammatory amplification and AFC impairment during ARDS (Fig. 4).

Furthermore, low oxygen or high carbon dioxide hypoxemia resulting from ventilation-perfusion mismatch and alveolar edema in ARDS can also downregulate the transportation of alveolar fluid. Hypoxia has been shown to directly induce protein kinase C-ζ (PKC-ζ) phosphorylation, leading to the endocytosis of Na,K-ATPase and subsequent reduction in AFC [198]. Similarly, elevated CO₂ levels during hypercapnia have been demonstrated to increase intracellular Ca²⁺ concentration, which activates the Ca²⁺/calmodulin-dependent kinase kinase-β (CAMKK-β) and AMPK to phosphorylate PKC-ζ, resulting in Na,K-ATPase endocytosis (Fig. 4) [199, 200]. Similar findings are reported recently that alveolar epithelium exposed to CO₂ activates ERK1/2 and the subsequent AMPK activation, leading to the activation of ubiquitin protein ligase neuronal precursor cell expressed developmentally down-regulated protein4-2 (Nedd4-2), which is a key molecular to drive the ubiquitination of ENaC. The activated Nedd4-2 thereby promotes alveolar edema via the induction of ENaC endocytosis [201, 202].

Conversely, there are many essential signaling pathways in enhancing AFC, suggesting their potential value for targeted reabsorption treatments of ARDS. An increasing number of studies have confirmed the beneficial effects of PI3K/AKT activation on AFC. It has been reported that the PI3K/Akt signaling pathway stimulates the serum and glucocorticoid-inducible kinase-1, which is a critical regulator of ENaC [203]. Han et al. [204] suggested that cAMP-regulated AFC enhancement by activating downstream PI3K/AKT signaling, which then phosphorylates Nedd4-2 to reduce ENaC degradation. Additionally, Magnani et al. [198] found that during prolonged hypoxia, HIF-1α signaling is activated to inhibit the endocytosis of Na,K-ATPase by causing degradation of PKC-ζ, which provides another potential therapeutic target for preserving AFC.

ROS-mediated signaling pathways

The excessive generation of ROS is well-established to be causative in the pathogenesis and progression of ARDS. In brief, the biological origins of ROS are associated with NADPH oxidase (NOX), xanthine oxidoreductase (XOR), nitric oxide synthase (NOS), and dysfunctional mitochondria [172]. NOX family is one of the most well-known sources of cytoplasmic ROS. NOX1, NOX2, and NOX4 are members of NOX family that have been detected to produce ROS in the lung tissue [205]. In addition, uncoupling of the dimeric endothelial NOS (eNOS) can also induce oxidative injury through a dysregulated NO response, which produces peroxynitrite to induce protein nitration [172]. Similarly, mitochondrial-derived oxidative stress led by mitochondrial-derived ROS (mtROS) is important for regulation of inflammatory progression under cellular stress conditions such as inflammation, hypoxia, mechanical stretch and Ca²⁺ influx [32]. The activation of these ROS-producing pathways is concomitant in the course of inflammation, leading to the amplification of tissue damage and pulmonary edema.

During ARDS, inflammation enhances ROS production by increasing the expression and activity of ROS-producing enzymes, which in turn aggravates inflammation by initiating proinflammatory signals. For example, NF-κB is demonstrated to be activated by NOX-derived ROS in LPS-induced ALI model, resulting in the expression of inflammatory cytokines [206]. The production of ROS by NOX2 in neutrophils plays a role in TNF-α-induced NF-κB-dependent lung inflammation in mice [207]. Similarly, mtROS promotes inflammation via initiating the activation of NLRP3 inflammasome and TLR9 signaling [208]. Recently, Zeng et al. [209] found that the TLR4 activation induces NOX2 assembly in alveolar epithelium, leading to ROS-stimulated ER stress and subsequent inflammation.

ROS has also been demonstrated to contribute to the disruption of the alveolar-capillary barrier, manifested by epithelial/endothelial cell death and loss of intercellular connections. ROS acts as an upstream signal of NLRP3 inflammasome activation, leading to cell pyroptosis in both epithelium and endothelium, ultimately increasing permeability [210, 211]. Ferroptosis is a newly recognized form of programmed cell death, which is manifested by elevated ROS levels and lipid peroxidation [212]. Studies have shown that excessive ferroptosis can aggravate lung tissue damage in ALI models [213, 214]. In addition to the direct disruption of intercellular junction proteins, ROS can also trigger associated signaling pathways that negatively regulate alveolar-capillary barrier [215]. Previous studies have demonstrated that eNOS uncoupling disrupts the pulmonary endothelial barrier [216]. Rafikov et al. [217] found that peroxynitrite produced by eNOS leads to RhoA nitration, which enhances cytoskeletal rearrangement to increase endothelial permeability. Recently, it has been reported that increased NOX4-dereived ROS during ALI disrupt the endothelial barrier by activating cytosolic Ca²⁺/calmodulin-dependent protein kinase II to trigger MLC-mediated cytoskeletal contraction, leading to the aggravation of sepsis-induced ALI [218].

Besides influencing cell–cell interactions, ROS also contributes to the reduction of AFC. It is implicated that mtROS released from mitochondria under hypoxia directly activates PKC-ζ, which further induces Na,K-ATPase endocytosis and impairs AFC [219]. NOX4-mediated ROS generation triggered by upstream TGF-β/Smad signaling has been shown to promote ENaC endocytosis, resulting in reducing alveolar fluid reabsorption [34]. Considering the involvement of ROS in ARDS development and progression, targeting the enzymes responsible for ROS generation could be a promising therapeutic approach for ARDS/ALI.

The current understanding is that the protective mechanism involves the nuclear factor erythroid 2-related factor (Nrf2) pathway against oxidative stress. Nrf2 is a transcription factor that remains sequestered in the cytosol when bound to Kelch-like ECH-associated protein 1 (Keap1) under resting condition. Upon oxidative stress, free Nrf2 translocates into the nucleus to initiate the expression of antioxidative genes such as heme oxygenase (HO), superoxide dismutases, glutathione peroxidase 4 and catalase [220]. However, during ARDS, the anti-oxidative effects by Nrf2 pathway are rapidly overwhelmed by excessive ROS production, or are dysregulated in damaged tissues, leading to aggravate oxidative injury [221, 222]. The importance of Nrf2 pathway in mediating antioxidant effects has been well characterized both in vivo and in vitro models of ALI/ARDS [102, 223]. In addition to considering general Nrf2 activation, researchers have explored alternative signaling pathways as potential targets for therapy. Guo et al. [224] have shown that hyperoxia exposure induces S-glutathionylation of fatty acid binding protein (FABP) 5 in macrophages, which enhances FABP5 ability to activate PPARβ/δ and inhibit inflammation. In their study, macrophage-specific glutaredoxin 1 deficiency alleviates ALI inflammation via enhancing the levels of S-glutathionylation FABP5. Besides, Cai et al. [225] have recently revealed the important role of the Notch pathway in regulating oxidative stress. Notch1/Hes1 activation inhibits NOX4 expression, leading to attenuate ROS-mediated endothelial cell apoptosis in burn-induced ALI model. Most recently, the activation of mitochondrial uncoupling proteins UCP2, a key regulator of intracellular ROS homeostasis, has been reported to suppress ROS generation through the activation of downstream Sirtuin 3 and the antioxidant peroxisome proliferator-activated receptor gamma coactivator 1-alpha in severe acute pancreatitis-induced ALI [226]. Thus, targeting these molecular pathways may present a promising therapeutic strategy for alleviating oxidative injury in ARDS.

Emerging pharmacologic therapies for ARDS

Pharmacotherapeutic approaches for ARDS have been attempted and tested for more than 50 years. Nonetheless, effective and targeted treatments for the disease remain elusive. Here, we will discuss the prospective pharmaceutical interventions associated with the pathophysiological and molecular targets, along with their effects on the relevant signal transduction pathways involved in ARDS management.

Pharmacologic therapies for ARDS

Therapeutic agents potentially targeting anti-inflammation

Numerous pharmacological agents have been reported to appear promising in ALI/ARDS for mitigating inflammatory responses. As PRRs play an important role in provoking inflammatory injury, therapeutic strategies focused on targeting these receptors have emerged (Table 2). Recently, it has been found that Cirsilineol [227], Diacerein [115], and Taurine [228] ameliorate inflammatory injury via the TLR4/NF-κB signaling pathway after ALI. Glycyrrhizin is reported to reduce LPS-induced ALI by TLR2 signaling inhibition [229]. Of note, a recent study showed that Omeprazole encapsulated by applying nanostructured lipid carriers effectively target lung macrophages and inhibit multiple TLR pathways, including TLR3, TLR4, and TLR7/8 in a murine model of ALI, supplying a new therapy for clinical needs of ARDS [230].

Table 2 Recent therapeutic agents and target pathways in ARDS

Full size table

For NLRs family, most of the research have focused on targeting the NLRP3 inflammasome to reduce the release of cytokines. Preclinical studies have shown that Glibenclamide [231], Tetracycline [232], and 4-hydroxynonena (an endogenous product of lipid peroxidation) [233] inhibit NLRP3 inflammasome activation independently of NF-κB signaling. Besides, an observational study for Tetracycline to investigate inflammasome activation in clinical ARDS is recruiting (NCT04079426). Similarly, limiting RAGE-mediated inflammation may be beneficial in ARDS treatment. It is reported that Dexmedetomidine [234], Calycosin [235], and Tanreqing [236] alleviate inflammation mediated by RAGE and TLR4 receptors via inhibiting HMGB1 signaling. Notably, a clinical trial of Dexmedetomidine for ARDS in critical care COVID-19 patients is under investigation (NCT04358627). The targeted inhibition of the cGAS-STING pathway is also a valuable idea, and several small-molecule inhibitors of cGAS-STING pathway, such as H-151 and RU.521 have been proven to alleviate lung injury in ALI models [237, 238].

The central role of NF-κB in proinflammatory signaling pathways makes it an attractive target for pharmaceutical intervention. Considering that NF-κB integrates numerous upstream signals, many targets indirectly inhibit NF-κB-mediated inflammation via modulating its upstream signaling. It has been shown that Chrysosplenol D [239], Daphnetin [165] and Inula japonica [102] ameliorate acute lung inflammation by suppressing the MAPK-mediated NF-κB pathway. The molecular BAP31 as well as Schisandrin B have presented therapeutic value by targeting MyD88 to reduce NF-κB activation in ALI mice [240, 241]. Moreover, there are a variety of targets that inhibit NF-κB signaling to negatively regulate NLRP3 inflammasome, such as Loganin [242], Dapagliflozin [243], Hederasaponin C [244], Artesunate [245], Syringaresinol [246], all of which have been studied in preclinical models of ALI/ARDS. Of note, the neutrophil elastase inhibitor Sivelestat and Simvastatin, two promising therapeutic drugs for treating ALI/ARDS, were also proven to target NF-κB inhibition in LPS-induced ALI [247, 248]. The administration of Sivelestat to ARDS patients has been confirmed to provide a 90-day mortality advantage by a retrospective study [249]. A phase III trial is in progress to assess the impact of Sivelestat on ARDS patients with sepsis (NCT04973670). For Simvastatin, a phase IIb randomized trial of Simvastatin therapy in ARDS patients did not yield improvements in clinical outcomes (ISRCTN88244364) [250]. However, a secondary analysis of this Simvastatin trial suggested that patients with hyperinflammatory subphenotypes who received Simvastatin exhibited lower 28-day mortality [251].

Given the promising efficacy of JAK inhibitors in the treatment of COVID-19-induced ARDS, the potential therapeutic effect by targeting JAK/STAT signaling pathway in ARDS has been revealed and may become a new strategy for treating other types of ARDS. Multiple clinical trials of JAK inhibitors including Baricitinib, Nezulcitinib, Pacritinib, Ruxolitinib, and Tofacitinib are completed or under investigation, and some published results have shown their safety and efficacy in COVID-19 patients [252]. Notably, Baricitinib has received approval for the treatment of hospitalized adults with COVID-19 who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation [253]. Besides, numerous preclinical animal studies have demonstrated the anti-inflammatory effects of JAK2/STAT3 inhibition in other etiologies-induced ARDS (Table 2) [254,255,256]. In addition, targeting the potent activator of JAK/STAT signaling, such as the IL-6 inhibitor Tocilizumab, has also shown beneficial effects in severe COVID-19 patients [257, 258]. Given the diverse etiology of ARDS, it is now imperative to conduct additional clinical trials for IL-6 inhibitors in non-COVID-19 ARDS patients.

Inactivation of MAPK signaling is also demonstrated to contribute to the anti-inflammatory effects in ARDS treatment. Nicotinamide [101], Irigenin [259] and β-Caryophyllene [260] have been recently found to inhibit MAPK signaling and reduce expression of inflammatory factors in ALI model. Particularly, Dilmapimod, a specific p38MAPK inhibitor, has been reported to have a satisfactory safety profile in trauma patients at risk of developing ARDS and to reduce the concentration of pro-inflammatory cytokines [261].

Recently, the aqueous extract of Descuraniae Semen (AEDS) as well as Vitamin-D are reported to possess an anti-inflammatory effect in preclinical ALI models via targeting the ER stress markers IRE1α and ATF6, respectively, offering new insights for the treatment of ALI/ARDS [262, 263]. However, a largest published randomised controlled trial showed no benefit of vitamin D on 90-day mortality in critically ill patients at high risk for ARDS [264]. With the development of more anti-inflammatory drugs, there is an increasing demand for additional high-quality clinical trials to confirm the therapeutic effects of these drugs in human ALI/ARDS patients.

Therapeutic agents potentially protecting the alveolar-capillary barrier

An alternative therapeutic strategy under consideration is to promote alveolar-capillary barrier function via enhancing intercellular junctions and diminishing pulmonary epithelial and endothelial cell injury. Oxypeucedanin [265], Forsythiae [266] and the andrographolide derivative AL-1 [267] have been found to contribute to the maintenance of alveolar-capillary integrity by increasing the expression of TJs proteins in ALI model. Pazopanib is shown to increase pulmonary barrier function via specifically inhibiting MAP3K2 and MAP3K3 phosphorylation in neutrophils, which leads to moderately ROS production that activates the Rac1-mediated protective effects in alveolar-capillary barrier in animal models. It also exhibits benefits in reducing lung edema in preliminary human study of five pairs of lung transplantation patients [268]. In recent years, some promising drugs have shown potential clinical benefits for treating ARDS through the protection of pulmonary endothelium. Research has shown that Ruscogenin upregulates the expression of p120 catenin and VE-cadherin via inactivating the TLR4/Src signaling in mice with sepsis-induced ALI [170]. Verdiperstat, a myeloperoxidase inhibitor, enhances VE-cadherin stability by reducing the activation of myeloperoxidase/μ-calpain/β-catenin signaling pathway on experimental ARDS in rats [269]. Blebbistatin is a myosin II inhibitor that resists pulmonary endothelial barrier dysfunction in mice. Results indicated that Blebbistatin downregulates the Wnt5a/β-catenin pathway and exerts a protective effect on lung injury [270]. In addition, certain compounds or drugs have been reported to mitigate alveolar epithelial and pulmonary endothelial cell death in preclinical models of ARDS, of which safety and efficacy remain to be further examined in clinical studies [153, 258, 271]. Of note, multiple RIPK1 inhibitors that suppress necroptosis have progressed beyond Phase I safety trials in human clinical studies for other inflammatory conditions like ulcerative colitis and rheumatoid arthritis [272]. Besides, Necrostatin-1 [273] and Aloperine [274] have obtained promising results in ARDS experimental models by reducing necroptosis and inflammation. Considering the vital role of necroptosis in the type of alveolar epithelial death in ARDS, these RIPK inhibitors merit further investigation in clinical trials [275].

Therapeutic agents potentially enhancing AFC

It is accepted that enhancement of AFC is pivotal for patient survival, thus the potentially effective drugs that promote excessive fluid clearance during ARDS merit investigation. β-adrenergic agonist is a commonly studied agent to improve AFC in animal models, mechanistically acting by increasing intracellular cAMP levels to increase the expression of ion transport channels [276]. Previous clinical trials involving Salbutamol for ARDS patients indicated poor tolerance and the potential to worsen mortality [277, 278]. However, a prospective study showed that inhalation of Formoterol and Budesonide reduced the incidence of ARDS [279]. A recent study reported similar results that inhaled salbutamol as monotherapy or combined with corticosteroids reduced the incidence of ARDS development among hospitalized patients [280]. Thus, this evidence may suggest the potential protective benefit of prior administration of β-adrenergic agonists in preventing ARDS. A synthetic peptide agent (a.k.a. AP301, solnatide) was shown to markedly reduce pulmonary edema by activating sodium channels in animal models of ARDS [281, 282]. A small phase 2 randomized blinded trial suggested that inhaled AP301 every 12 h for 7 days was shown to decrease pulmonary edema and reduce ventilation pressures in patients with ARDS [283]. Another trial testing AP301 in patients with moderate–severe ARDS is currently enrolling (NCT03567577).

Moreover, the important role of the macrophage-derived specialized pro-resolving mediators (SPMs) in promoting AFC during ARDS has been gradually recognized [284]. For example, the resolvin conjugates in tissue regeneration 1 [285] as well as the maresin conjugates in tissue regeneration 1 [204] belong to SPMs, which have been recently implicated to upregulate ENaC and Na,K-ATPase by activating the cAMP/PI3K/AKT signaling pathways, and results in alleviating pulmonary edema in preclinical ARDS models. However, there is a lack of significant clinical studies of either administered exogenously or induction of endogenous SPMs in ARDS patients. Besides, Ursodeoxycholic acid [286] and Aldosterone [203] have been proven to exert therapeutic effects in mitigating LPS-induced pulmonary edema in animal models by modulating the cAMP/PI3K/AKT pathway. Further researches into the efficacy and safety of these drugs in ARDS patients are required.

Therapeutic agents potentially attenuating oxidative injuries

Considering the crucial role of oxidative injury in ARDS pathogenesis, therapeutic targets for suppressing oxidative stress have aroused considerable attention. A variety of antioxidant therapies including vitamin C supplementation or N-acetylcysteine administration, have been applied to ARDS patients. Regarding vitamin C, a phase 2 clinical trial involving 167 patients with ARDS and sepsis found that high-dose vitamin C infusion, when compared to a placebo, did not significantly reduce organ failure or improve inflammatory biomarkers, but improved the secondary outcomes of 28-day mortality, ICU-free days, and hospital-free days [287]. N-acetylcysteine is well-known for its mucolytic effect and robust antioxidant activity. However, the usefulness of N-acetylcysteine in ARDS patients is controversial [288, 289]. Recently, its potential to inhibit the progression of COVID-19 has rendered it a highly promising therapy for the disease [290].

Moreover, the Nrf2 pathway plays a crucial role in protection against oxidative lung injuries during ARDS, and thus antioxidants activating Nrf2 pathway may be an effective intervention. It has been found that Panaxydol [291], Melatonin [292] and Sitagliptin [293] act on Nrf2 pathway to increase the expression of antioxidants in lung tissue, leading to alleviate oxidative injury in animal ARDS models. But further clinical trials are certainly required to determine its precise efficacy in protecting against ARDS. In addition, targeting the enzymes responsible for ROS generation might offer a promising therapeutic approach for ARDS. Pharmacological inhibitors of NOX2, such as Quercetin [294], Apocynin [295] and VAS2870 [215], as well as NOX1/4 inhibitor G137831 [296], have been shown to protect lung tissue damage induced by oxidative stress during ARDS. However, these have only undergone preclinical studies and evidence in human is still required.

MicroRNAs in ARDS

In recent times, there has been a growing focus on the involvement of microRNAs (miRNAs) in ARDS. MiRNAs are a category of small noncoding RNAs that modulate gene expression by either inhibiting the translation of target mRNAs or facilitating the early degradation of complementary mRNAs [106]. Multiple results from preclinical studies have indicated that miRNAs may play pivotal roles in the pathophysiology of ARDS by targeting specific genes to regulate the signaling pathways. These regulatory effects extend to cellular, receptor, signaling pathways, and gene transcription levels [297]. For instance, Xu et al. [298] found that increased miR-199a-3p exacerbates LPS-induced ARDS via silencing PAK4 expression in AMS, resulting in the release of pro-inflammatory autophagosomes and cytokines in mice, all of which can be reversed by miR-199a-3p inhibitors. Yang et al. [299] observed that miR-16 overexpression mitigated LPS-induced ALI in mice by inhibiting TLR4 expression and subsequently downregulating the TLR4/NF-κB signaling pathways in mice. Furthermore, miRNA localization is a critical factor influencing its function. Extracellular miR146a-5p has been reported to trigger TLR7-dependent inflammation and endothelial barrier disruption while also exerting intracellular negative regulation of TLR signaling by targeting IRAK1 and TRAF6 expression [300, 301]. Recent research on miRNAs and their roles in preclinical ALI/ARDS models have been summarized in the table [298, 302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323] (Table 3).

Table 3 The potential therapeutic miRNAs in ARDS

Full size table

Of note, the influence of long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) upon microRNA function has also emerged rapidly, which regulates the downstream pathways by sequestering and competitively suppressing miRNA activity. For example, lncRNA NLRP3 promotes NLRP3 inflammasome activation by sponging miR-138-5p [317]. Similarly, circRNA N4bp1 that increased in ARDS patients has been demonstrated to facilitate M1 polarization via targeting miR-138-5p in CLP-induced ALI of mice [322]. lncRNA MINCR negatively regulates miR-146b-5p to activate the NF-κB-mediated inflammation [311].

Considering the regulatory roles of miRNAs in animal models of ARDS, the concept of employing miRNA mimics or antagomirs (synthetic miRNA inhibitors with sequences complementary to specific miRNAs) emerges as an appealing option for targeted therapy in ALI/ARDS. At present, there are few clinical trials involving miRNAs for diagnosing or treating ALI/ARDS. One ongoing clinical trial is currently recruiting participants with the expectation of validating several non-coding RNAs as new biomarkers for predicting the severity of ALI/ARDS in patients (NCT03766204). Another trial that aims to explore the expressions of miR-27b and Nrf2 in the development and treatment of ARDS patients is also recruiting (NCT04937855). Hence, there is an urgent need for clinical trials investigating the potential therapeutic targeting of miRNAs in ALI/ARDS, and the clinical application of miRNAs in ALI/ARDS deserves significant attention.

Mesenchymal stromal cell therapy

Mesenchymal stromal cell (MSC) therapy has shown promising results in ARDS, thanks to its multi-directional differentiation potential, migration ability and immunomodulatory effects [324]. It spontaneously migrates to the injured region to influence the tissue microenvironment by secreting soluble bioactive molecules or cell–cell contact, leading to alleviate inflammation, enhancing epithelial and endothelial regeneration and improving AFC [325]. Preclinical studies have demonstrated that MSCs participate in a variety of signaling pathways associated with the pathophysiology of ARDS. Administration of human umbilical cord-derived MSCs alleviated inflammation in LPS-induced ALI of mice via downregulation of NF-κB signaling [326]. MSC-expressed jagged-1 interacts with Notch2 on mature DCs, which differentiate into regulatory DCs to negatively regulate inflammation [85]. MSC has also been demonstrated to promote barrier function and restoration of alveolar epithelium by activating Wnt/β-catenin signaling pathway in ALI mice [176]. Marrow-derived MSCs are reported to exert antioxidant effects via upregulating Nrf2/HO-1 signaling in rat models with LPS-induced ALI [327]. Inhibition of the Hippo signaling increased MSCs differentiation into ATII cells and alleviated LPS-induced ALI [328].

The safety and efficacy of transplanted MSCs for patients with ARDS have been substantiated by many clinical trials [329,330,331,332]. A phase 1/2 trial demonstrated the safety of MSC administration in ARDS patients, with the potential to reduce 28-day mortality and the requirement for ventilator support [333]. The transplantation of menstrual blood-derived MSCs has the potential to lower mortality in patients with H7N9 virus-induced ARDS, as observed during a five-year follow-up period [334]. In addition, clinical trials are currently investigating the therapeutic benefits of MSCs for COVID-19, which provide a promising opportunity for patients with pulmonary damage [335]. However, a recent multicenter, randomized, double-blind, placebo-controlled trial (NCT 03042143) has found that patients with moderate to severe COVID-19-related ARDS do not benefit from ORBCEL-C (CD362-enriched umbilical cord-derived MSCs), although the application of these MSC cells is considered safe [336]. For further information about the properties and functions of MSCs in ARDS, consider consulting the reviews by Fernandez-Francos et al. [337] and Qin and Zhao [325].

Subphenotypes in ARDS and prospects for targeted therapies

While numerous preclinical studies on pharmacological treatments for ARDS have shown promise, none have yet demonstrated a significant impact on ARDS mortality in clinical trials. The potential reasons may be partially due to the heterogeneity of ARDS [338]. More homogeneous subgroups of ARDS patients can be identified based on physiological, clinical, and biological characteristics [339]. By integrating clinical and biological characteristics, Calfee and colleagues identified a hyper-inflammatory subphenotype characterized by increased inflammation and higher mortality compared to the hypo-inflammatory subphenotype [340]. Subsequent studies have reported similar findings [341,342,343]. These prognostic enrichments can identify a higher likelihood of a poor outcome and may assist in making bedside healthcare decisions.

On the other hand, predictive enrichment aids in the selection of patients with a higher likelihood of positive responses to specific treatments or in the identification of patients more likely to benefit from particular interventions based on underlying mechanisms and biological characteristics [339]. Physiological and clinical phenotyping for predictive enrichment has yielded intriguing findings. For instance, Calfee CS et al. discovered elevated levels of epithelial injury biomarkers in patients with direct ARDS [344]. Additionally, some research have shown that recruitment maneuvers are less effective in primary ARDS rat models, while methylprednisolone proves to be more effective in mitigating the inflammatory response [345, 346]. While pre-randomization trials involving biologic phenotyping for predictive enrichment are infrequent in clinical practice due to the limited availability of biomarker tests, retrospective studies have demonstrated varying responses of hypo- and hyper-inflammatory phenotypes to interventions, such as positive end-expiratory pressure, fluid management strategies, and simvastatin [251, 339, 340, 342].

Given that hypo- and hyper-inflammatory phenotypes provide only a general characterization of inflammation in ARDS, it is worthwhile to identify more specific subphenotypes based on the main signaling pathways. Further evaluation of targeted treatments has the potential to enhance therapeutic responses and improve the ability to identify effective interventions. For example, Bos et al. reported elevated expression of oxidative phosphorylation genes in the “reactive” subphenotype, as identified by plasma protein biomarkers. The authors suggested further investigation of interventions targeting this pathway in patients with “reactive” subphenotype [347]. However, as summarized by Wilson JG et al., the use of metabolomics, transcriptomics, genomics, and signaling pathway characteristics for ARDS phenotyping and predictive enrichment is still in its early stages [339].

Conclusions

ARDS is a syndrome characterized by high morbidity and mortality. Despite substantial progress has been made over the past five decades in understanding the pathogenesis and pathophysiology of ARDS, few pharmacological interventions have shown a clear mortality benefit in its therapy. Clinical treatment mainly relies on supportive care with mechanical ventilation. Therefore, there is an urgent need for novel therapeutic strategies in ARDS treatment. As recent studies have shown, the developed therapeutic strategies have taken into consideration the regulation of signaling pathways involved in the pathophysiological mechanisms of ARDS. In this review, we combed the existing evidence of molecular mechanisms in ARDS pathophysiology, involving inflammation, increased alveolar-capillary permeability, impaired AFC and oxidative stress. Moreover, we reviewed the recent promising therapeutic strategies for managing ARDS, highlighting the pathophysiological basis and the influences on cell signaling molecule expression for their use.

Of note, pharmacologic therapies that achieved promising effects in preclinical studies have often failed to show efficiency in clinical trials involving unselected ARDS populations. These outcomes can be attributed to the clinical and biological heterogeneity of ARDS patients. Secondary analysis of data from randomized controlled trials has revealed distinct responses to simvastatin treatment, fluid strategy, and positive end-expiratory pressure strategy between the hypo-inflammatory and hyper-inflammatory subphenotypes [251, 340, 342]. By employing CT imaging data and physiological characteristics, latent class analysis revealed the presence of two subphenotypes exhibiting varying responses to lung recruitment [348]. In view of these findings, it is essential to identify homogenous biological and clinical phenotypes of ARDS and to conduct further investigations into the underlying variations in molecular mechanisms among different subphenotypes. These efforts are critical for advancing more effective targeted pharmacologic therapies and achieving precision medicine.

Availability of data and materials

Not applicable.

Abbreviations

AECs:: Alveolar epithelial cells
AEDS:: Aqueous extract of Descuraniae Semen
AFC:: Alveolar fluid clearance
AIM2:: Absent in melanoma 2
AJs:: Adherens junctions
AKT:: Protein kinase B
ALI:: Acute lung injury
ALK1:: Activin receptor-like kinase 1
AMPK:: AMP-activated protein kinase
AMs:: Alveolar macrophages
Ang:: Angiopoietin
AP-1:: Activator protein-1
ARDS:: Acute respiratory distress syndrome
ASC:: Apoptosis-associated speck-like protein containing a CARD
ASK1:: Apoptosis signal-regulating kinase 1
ATF6:: Activating transcription factor 6
BALF:: Bronchoalveolar lavage fluid
BAP31:: B-cell receptor associated protein 31
BMP9:: Bone morphogenetic protein 9
CAMKK-β:: Calmodulin-dependent kinase kinase-β
cAMP:: Cyclic adenosine monophosphate
CDSs:: Cytoplasmic DNA sensors
CFTR:: Cystic fibrosis transmembrane conductance regulator
cGAMP:: Cyclic GMP-AMP
cGAS:: Cyclic GMP-AMP synthase
circRNAs:: Circular RNAs
COVID-19:: Coronavirus disease 2019
CREB:: CAMP response element binding
DAMPs:: Damage-associated molecular patterns
DCs:: Dendritic cells
Drp1:: Dynamin-related protein 1
EMT:: Epithelial–mesenchymal transition
ENaC:: Epithelial Na⁺ channel
eNOS:: Endothelial NOS
ER:: Endoplasmic reticulum
ERK:: Extracellular signal-regulated kinase
FABP:: Fatty acid binding protein
FasL:: Fas ligand
FPR:: N-formyl peptide receptor
G-CSF:: Granulocyte colony-stimulating factor
GPCRs:: G-protein-coupled receptors
Hes1:: Hairy/Enhancer of Split 1
HIF-1α:: Hypoxia-inducible factor-1α
HIF-2α:: Hypoxia-inducible factor-2α
HMGB1:: High-mobility group box 1
HO:: Heme oxygenase
HSP:: Heat shock protein
IFNs:: Type I-interferons
IL-1:: Interleukin-1
IRE1α:: Inositol requiring kinase 1α
IRFs:: Interferon regulatory factors
IκB:: NF-κB inhibitor
JAK:: Janus kinase
JAMs:: Junctional adhesion molecules
JNK:: C-Jun N-terminal kinase
Keap1:: Kelch-like ECH-associated protein 1
lncRNAs:: Long non-coding RNAs
LPS:: Lipopolysaccharide
MAPK:: Mitogen-activated protein kinase
MAVS:: Mitochondrial antiviral signaling protein
MCTR1:: Maresin conjugates in tissue regeneration 1
MDA5:: Melanoma differentiation-associated gene 5
miRNAs:: MicroRNAs
MLC:: Myosin light chain
MLKL:: Mixed lineage kinase domain-like protein
MSC:: Mesenchymal stromal cell
mTOR:: Mammalian target of the rapamycin
mtROS:: Mitochondrial-derived ROS
MyD88:: Myeloid differentiation primary response gene 88
Na,K-ATPase:: Sodium–potassium adenosine triphosphatase
NAIP:: Neuronal apoptosis inhibitory protein
Nedd4-2:: Neuronal precursor cell expressed developmentally down-regulated protein4-2
NETs:: Neutrophil extracellular traps
NF-κB:: Nuclear factor-κB
NLRC::: Nucleotide-binding oligomerization domain like receptor subfamily C
NLRP:: Nucleotide-binding domain leucine-rich repeat protein
NLRs:: Nucleotide-binding leucine-rich repeat receptors
NOD:: Nucleotide-binding oligomerization domain
NOS:: Nitric oxide synthase
NOX:: NADPH oxidase
Nrf2::: Nuclear factor erythroid 2-related factor
PAMPs:: Pathogen-associated molecular patterns
PERK:: Protein kinase RNA-like ER kinase
PI3K:: Phosphatidylinositol 3-kinase
PKC-ζ:: Protein kinase C-ζ
PRRs:: Pattern recognition receptors
RAGEs:: Receptors for advanced glycation end products
RCTR1:: Resolvin conjugates in tissue regeneration 1
RIG-I:: Retinoic acid-inducible gene I
RIPK:: Receptor-interacting protein kinase
RLRs:: RIG-I-like receptors
Robo4:: Roundabout 4
ROCK:: Rho-associated protein kinase
ROS:: Reactive oxygen species
S1P:: Sphingosine-1 phosphate
SARS-CoV-2:: Severe acute respiratory syndrome coronavirus 2
Smad:: Small Mothers against Decapentaplegic
SPMs:: Specialized pro-resolving mediators
STAT:: Signal transducer and activator of transcription
STING:: Stimulator of the interferon gene
TGF-β:: Transforming growth factor-β
Th17:: T helper 17 cell
TJs:: Tight junctions
TLRs:: Toll-like receptors
TNFR:: TNF-receptor
TNF-α:: Tumor necrosis factor-α
TRADD:: TNFR-associated death domain
TRAF:: TNFR–associated factor
TRAIL:: TNF-related apoptosis-inducing ligand
TRAILR:: TNF-related apoptosis-inducing ligand receptor
TRIF:: Toll/interleukin-1 receptor-domain-containing adaptor-inducing interferon-β
TRP:: Transient receptor potential
VE-cadherin:: Vascular endothelial cadherin
VEGF:: Vascular endothelial growth factor
VE-PTP:: Vascular endothelial protein tyrosine phosphatase
VILI:: Ventilator-induced lung injury
XOR:: Xanthine oxidoreductase
YAP:: Yes-associated protein
Zos:: Zonula occludens

References

Qadir N, Chang SY. Pharmacologic treatments for acute respiratory distress syndrome. Crit Care Clin. 2021;37:877–93.
Article PubMed PubMed Central Google Scholar
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800.
Article CAS PubMed Google Scholar
Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021;398:622–37.
Article CAS PubMed PubMed Central Google Scholar
Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5:18.
Article PubMed PubMed Central Google Scholar
Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev. 2003;14:523–35.
Article CAS PubMed Google Scholar
Opitz B, van Laak V, Eitel J, Suttorp N. Innate immune recognition in infectious and noninfectious diseases of the lung. Am J Respir Crit Care Med. 2010;181:1294–309.
Article CAS PubMed Google Scholar
Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006;27:337–49.
Article PubMed Google Scholar
Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519–31.
Article CAS PubMed Google Scholar
Hotez PJ, Bottazzi ME, Corry DB. The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes Infect. 2020;22:165–7.
Article CAS PubMed PubMed Central Google Scholar
Tan LY, Komarasamy TV, Rmt BV. Hyperinflammatory immune response and COVID-19: a double edged sword. Front Immunol. 2021;12: 742941.
Article CAS PubMed PubMed Central Google Scholar
Zuniga M, Gomes C, Carsons SE, Bender MT, Cotzia P, Miao QR, et al. Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients. Eur Respir J. 2021;58:2100918.
Article CAS PubMed PubMed Central Google Scholar
Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet. 2022;400:1145–56.
Article PubMed Google Scholar
Rocco PR, Pelosi P. Pulmonary and extrapulmonary acute respiratory distress syndrome: myth or reality? Curr Opin Crit Care. 2008;14:50–5.
Article PubMed Google Scholar
Deng JC, Standiford TJ. The systemic response to lung infection. Clin Chest Med. 2005;26:1–9.
Article PubMed Google Scholar
Vitenberga Z, Pilmane M. Inflammatory, anti-inflammatory and regulatory cytokines in relatively healthy lung tissue as an essential part of the local immune system. Biomed Pap. 2017;161:164–73.
Article Google Scholar
Quinton LJ, Walkey AJ, Mizgerd JP. Integrative physiology of pneumonia. Physiol Rev. 2018;98:1417–64.
Article CAS PubMed PubMed Central Google Scholar
Jouan Y, Baranek T, Si-Tahar M, Paget C, Guillon A. Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS. Crit Care. 2021;25:120.
Article PubMed PubMed Central Google Scholar
Bendib I, Beldi-Ferchiou A, Schlemmer F, Surenaud M, Maitre B, Plonquet A, et al. Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS. Crit Care. 2021;25:23.
Article PubMed PubMed Central Google Scholar
Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol. 2008;28:223–32.
Article CAS PubMed Google Scholar
Dolmatova EV, Wang K, Mandavilli R, Griendling KK. The effects of sepsis on endothelium and clinical implications. Cardiovasc Res. 2021;117:60–73.
Article CAS PubMed Google Scholar
Radeva MY, Waschke J. Mind the gap: mechanisms regulating the endothelial barrier. Acta Physiol (Oxf). 2018;222: e12860.
Article Google Scholar
He Y, Yuan X, Zuo H, Sun Y, Feng A. Berberine exerts a protective effect on gut-vascular barrier via the modulation of the Wnt/beta-catenin signaling pathway during sepsis. Cell Physiol Biochem. 2018;49:1342–51.
Article CAS PubMed Google Scholar
Yang R, Zhang X. A potential new pathway for heparin treatment of sepsis-induced lung injury: inhibition of pulmonary endothelial cell pyroptosis by blocking hMGB1-LPS-induced caspase-11 activation. Front Cell Infect Microbiol. 2022;12: 984835.
Article CAS PubMed PubMed Central Google Scholar
Folkesson HG, Matthay MA. Alveolar epithelial ion and fluid transport: recent progress. Am J Respir Cell Mol Biol. 2006;35:10–9.
Article CAS PubMed PubMed Central Google Scholar
Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377:562–72.
Article CAS PubMed Google Scholar
Lee JW, Fang X, Dolganov G, Fremont RD, Bastarache JA, Ware LB, et al. Acute lung injury edema fluid decreases net fluid transport across human alveolar epithelial type II cells. J Biol Chem. 2007;282:24109–19.
Article CAS PubMed Google Scholar
Morty RE, Eickelberg O, Seeger W. Alveolar fluid clearance in acute lung injury: what have we learned from animal models and clinical studies? Intensive Care Med. 2007;33:1229–40.
Article CAS PubMed PubMed Central Google Scholar
Zhou G, Dada LA, Sznajder JI. Regulation of alveolar epithelial function by hypoxia. Eur Respir J. 2008;31:1107–13.
Article CAS PubMed Google Scholar
Vadasz I, Sznajder JI. Gas exchange disturbances regulate alveolar fluid clearance during acute lung injury. Front Immunol. 2017;8:757.
Article PubMed PubMed Central Google Scholar
Huppert LA, Matthay MA, Ware LB. Pathogenesis of acute respiratory distress syndrome. Semin Respir Crit Care Med. 2019;40:31–9.
Article PubMed PubMed Central Google Scholar
Ward PA. Oxidative stress: acute and progressive lung injury. Ann N Y Acad Sci. 2010;1203:53–9.
Article CAS PubMed Google Scholar
Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20:1126–67.
Article CAS PubMed PubMed Central Google Scholar
Cen M, Ouyang W, Zhang W, Yang L, Lin X, Dai M, et al. MitoQ protects against hyperpermeability of endothelium barrier in acute lung injury via a Nrf2-dependent mechanism. Redox Biol. 2021;41: 101936.
Article CAS PubMed PubMed Central Google Scholar
Peters DM, Vadasz I, Wujak L, Wygrecka M, Olschewski A, Becker C, et al. TGF-β directs trafficking of the epithelial sodium channel ENaC which has implications for ion and fluid transport in acute lung injury. Proc Natl Acad Sci U S A. 2014;111:E374–83.
Article CAS PubMed Google Scholar
Sarma JV, Ward PA. Oxidants and redox signaling in acute lung injury. Compr Physiol. 2011;1:1365–81.
Article PubMed Google Scholar
Root-Bernstein R. Innate receptor activation patterns involving TLR and NLR synergisms in COVID-19, ALI/ARDS and sepsis cytokine storms: a review and model making novel predictions and therapeutic suggestions. Int J Mol Sci. 2021;22:2108.
Article CAS PubMed PubMed Central Google Scholar
Xiang M, Fan J. Pattern recognition receptor-dependent mechanisms of acute lung injury. Mol Med. 2010;16:69–82.
Article CAS PubMed Google Scholar
Li H, Pan P, Su X, Liu S, Zhang L, Wu D, et al. Neutrophil extracellular traps are pathogenic in ventilator-induced lung injury and partially dependent on TLR4. Biomed Res Int. 2017;2017:8272504.
Article PubMed PubMed Central Google Scholar
Mallavia B, Liu F, Lefrancais E, Cleary SJ, Kwaan N, Tian JJ, et al. Mitochondrial DNA stimulates TLR9-dependent neutrophil extracellular trap formation in primary graft dysfunction. Am J Respir Cell Mol Biol. 2020;62:364–72.
Article CAS PubMed PubMed Central Google Scholar
McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, et al. Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery. J Crit Care. 2014;29(1133):e1-5.
Google Scholar
Sekheri M, El Kebir D, Edner N, Filep JG. 15-Epi-LXA(4) and 17-epi-RvD1 restore TLR9-mediated impaired neutrophil phagocytosis and accelerate resolution of lung inflammation. Proc Natl Acad Sci USA. 2020;117:7971–80.
Article CAS PubMed PubMed Central Google Scholar
Su K, Bo L, Jiang C, Deng X, Zhao YY, Minshall RD, et al. TLR4 is required for macrophage efferocytosis during resolution of ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2021;321:L787-801.
Article CAS PubMed PubMed Central Google Scholar
McVey MJ, Steinberg BE, Goldenberg NM. Inflammasome activation in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2021;320:L165–78.
Article CAS PubMed Google Scholar
Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 2009;113:2324–35.
Article CAS PubMed PubMed Central Google Scholar
Bai B, Yang Y, Wang Q, Li M, Tian C, Liu Y, et al. NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis. 2020;11:776.
Article CAS PubMed PubMed Central Google Scholar
Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20:3328.
Article CAS PubMed PubMed Central Google Scholar
Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5’-phosphates. Science. 2006;314:997–1001.
Article CAS PubMed Google Scholar
Kumagai Y, Takeuchi O, Kato H, Kumar H, Matsui K, Morii E, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity. 2007;27:240–52.
Article CAS PubMed Google Scholar
Brisse M, Ly H. Comparative structure and function analysis of the rig-I-Like receptors: RIG-I and MDA5. Front Immunol. 2019;10:1586.
Article CAS PubMed PubMed Central Google Scholar
Ablasser A, Hur S. Regulation of cGAS- and RLR-mediated immunity to nucleic acids. Nat Immunol. 2020;21:17–29.
Article CAS PubMed Google Scholar
Hagau N, Slavcovici A, Gonganau DN, Oltean S, Dirzu DS, Brezoszki ES, et al. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection. Crit Care. 2010;14:R203.
Article PubMed PubMed Central Google Scholar
Ma R, Serrano TPO, Davis J, Prigge AD, Ridge KM. The cGAS-STING pathway: the role of self-DNA sensing in inflammatory lung disease. FASEB J. 2020;34:13156–70.
Article CAS PubMed Google Scholar
Wang J, Li R, Peng Z, Hu B, Rao X, Li J. HMGB1 participates in LPS-induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF-κB signaling pathways. Int J Mol Med. 2020;45:61–80.
CAS PubMed Google Scholar
Wu B, Xu MM, Fan C, Feng CL, Lu QK, Lu HM, et al. STING inhibitor ameliorates LPS-induced ALI by preventing vascular endothelial cells-mediated immune cells chemotaxis and adhesion. Acta Pharmacol Sin. 2022;43:2055–66.
Article CAS PubMed Google Scholar
Hsieh PC, Wu YK, Yang MC, Su WL, Kuo CY, Lan CC. Deciphering the role of damage-associated molecular patterns and inflammatory responses in acute lung injury. Life Sci. 2022;305: 120782.
Article CAS PubMed Google Scholar
Creagh-Brown BC, Quinlan GJ, Evans TW, Burke-Gaffney A. The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target? Intensive Care Med. 2010;36:1644–56.
Article CAS PubMed Google Scholar
Guo WA, Knight PR, Raghavendran K. The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome. Intensive Care Med. 2012;38:1588–98.
Article CAS PubMed Google Scholar
Zhang H, Tasaka S, Shiraishi Y, Fukunaga K, Yamada W, Seki H, et al. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med. 2008;178:356–62.
Article CAS PubMed Google Scholar
Lee BH, Hwang DM, Palaniyar N, Grinstein S, Philpott DJ, Hu J. Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. PLoS ONE. 2012;7: e35812.
Article CAS PubMed PubMed Central Google Scholar
Mishra A. New insights of P2X7 receptor signaling pathway in alveolar functions. J Biomed Sci. 2013;20:26.
Article CAS PubMed PubMed Central Google Scholar
Liu Z, Wang P, Lu S, Guo R, Gao W, Tong H, et al. Liquiritin, a novel inhibitor of TRPV1 and TRPA1, protects against LPS-induced acute lung injury. Cell Calcium. 2020;88: 102198.
Article CAS PubMed Google Scholar
Li C, Bo L, Liu Q, Liu W, Chen X, Xu D, et al. Activation of TRPV1-dependent calcium oscillation exacerbates seawater inhalation-induced acute lung injury. Mol Med Rep. 2016;13:1989–98.
Article CAS PubMed PubMed Central Google Scholar
Hamanaka K, Jian MY, Weber DS, Alvarez DF, Townsley MI, Al-Mehdi AB, et al. TRPV4 initiates the acute calcium-dependent permeability increase during ventilator-induced lung injury in isolated mouse lungs. Am J Physiol Lung Cell Mol Physiol. 2007;293:L923–32.
Article CAS PubMed Google Scholar
Zhang X, Wang T, Yuan ZC, Dai LQ, Zeng N, Wang H, et al. Mitochondrial peptides cause proinflammatory responses in the alveolar epithelium via FPR-1, MAPKs, and AKT: a potential mechanism involved in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315:L775–86.
Article CAS PubMed Google Scholar
Chen CY, Tsai YF, Huang WJ, Chang SH, Hwang TL. Propofol inhibits endogenous formyl peptide-induced neutrophil activation and alleviates lung injury. Free Radic Biol Med. 2018;129:372–82.
Article CAS PubMed Google Scholar
Halpin-Veszeleiova K, Hatfield SM. Therapeutic targeting of hypoxia-A2-adenosinergic pathway in COVID-19 patients. Physiology (Bethesda). 2022;37:46–52.
CAS PubMed Google Scholar
Li X, Berg NK, Mills T, Zhang K, Eltzschig HK, Yuan X. Adenosine at the interphase of hypoxia and inflammation in lung injury. Front Immunol. 2020;11: 604944.
Article CAS PubMed Google Scholar
Bowser JL, Lee JW, Yuan X, Eltzschig HK. The hypoxia-adenosine link during inflammation. J Appl Physiol. 1985;2017(123):1303–20.
Google Scholar
Eckle T, Kewley EM, Brodsky KS, Tak E, Bonney S, Gobel M, et al. Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury. J Immunol. 2014;192:1249–56.
Article CAS PubMed Google Scholar
Ko IG, Hwang JJ, Chang BS, Kim SH, Jin JJ, Hwang L, et al. Polydeoxyribonucleotide ameliorates lipopolysaccharide-induced acute lung injury via modulation of the MAPK/NF-κB signaling pathway in rats. Int Immunopharmacol. 2020;83: 106444.
Article CAS PubMed Google Scholar
Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol. 2005;3: e174.
Article PubMed PubMed Central Google Scholar
Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46:705–16.
Article CAS PubMed Google Scholar
Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.
Article CAS PubMed Google Scholar
Millar MW, Fazal F, Rahman A. Therapeutic targeting of NF-κB in acute lung injury: a double-edged sword. Cells. 2022;11:3317.
Article CAS PubMed PubMed Central Google Scholar
Liu Y, Chacko BK, Ricksecker A, Shingarev R, Andrews E, Patel RP, et al. Modulatory effects of hypercapnia on in vitro and in vivo pulmonary endothelial-neutrophil adhesive responses during inflammation. Cytokine. 2008;44:108–17.
Article CAS PubMed PubMed Central Google Scholar
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39:517–28.
Article CAS PubMed Google Scholar
Lee JW, Chun W, Lee HJ, Min JH, Kim SM, Seo JY, et al. The role of macrophages in the development of acute and chronic inflammatory lung diseases. Cells. 2021;10:897.
Article CAS PubMed PubMed Central Google Scholar
Fan J, Ye RD, Malik AB. Transcriptional mechanisms of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1037–50.
Article CAS PubMed Google Scholar
Song D, Ye X, Xu H, Liu SF. Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood. 2009;114:2521–9.
Article CAS PubMed PubMed Central Google Scholar
Kiyokawa H, Morimoto M. Notch signaling in the mammalian respiratory system, specifically the trachea and lungs, in development, homeostasis, regeneration, and disease. Dev Growth Differ. 2020;62:67–79.
Article PubMed Google Scholar
Gajjela BK, Zhou MM. Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling. Drug Discov Today. 2022;27:390.
Article CAS PubMed Google Scholar
Bai X, Li J, Li L, Liu M, Liu Y, Cao M, et al. Extracellular vesicles from adipose tissue-derived stem cells affect notch-miR148a-3p Axis to regulate polarization of macrophages and alleviate sepsis in mice. Front Immunol. 2020;11:1391.
Article CAS PubMed PubMed Central Google Scholar
Bai X, He T, Liu Y, Zhang J, Li X, Shi J, et al. Acetylation-dependent regulation of notch signaling in macrophages by SIRT1 affects sepsis development. Front Immunol. 2018;9:762.
Article PubMed PubMed Central Google Scholar
Li M, Zhao Y, He J, Deng W, Cheng L, Jiang Z, et al. Protein kinase C theta inhibition attenuates lipopolysaccharide-induced acute lung injury through notch signaling pathway via suppressing Th17 cell response in mice. Inflammation. 2019;42:1980–9.
Article CAS PubMed Google Scholar
Lu Z, Meng S, Chang W, Fan S, Xie J, Guo F, et al. Mesenchymal stem cells activate Notch signaling to induce regulatory dendritic cells in LPS-induced acute lung injury. J Transl Med. 2020;18:241.
Article CAS PubMed PubMed Central Google Scholar
Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.
Article PubMed PubMed Central Google Scholar
Wang HZ, Yang C, Zhang BY, Li N, Han Z, Chen F. Influence of mesenchymal stem cells on respiratory distress syndrome in newborn swines via the JAK-STAT signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23:7550–6.
PubMed Google Scholar
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6: a016295.
Article PubMed PubMed Central Google Scholar
Chen X, Tang J, Shuai W, Meng J, Feng J, Han Z. Macrophage polarization and its role in the pathogenesis of acute lung injury/acute respiratory distress syndrome. Inflamm Res. 2020;69:883–95.
Article CAS PubMed PubMed Central Google Scholar
Zhang Y, Gao Z, Jiang F, Yan H, Yang B, He Q, et al. JAK-STAT signaling as an ARDS therapeutic target: status and future trends. Biochem Pharmacol. 2023;208: 115382.
Article CAS PubMed Google Scholar
Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6:255.
Article CAS PubMed PubMed Central Google Scholar
Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52:731–3.
Article CAS PubMed PubMed Central Google Scholar
Nakayama T, Hirahara K, Onodera A, Endo Y, Hosokawa H, Shinoda K, et al. Th2 cells in health and disease. Annu Rev Immunol. 2017;35:53–84.
Article CAS PubMed Google Scholar
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787–95.
Article CAS PubMed PubMed Central Google Scholar
Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75:50–83.
Article CAS PubMed PubMed Central Google Scholar
Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807–69.
Article CAS PubMed Google Scholar
Cong Z, Li D, Tao Y, Lv X, Zhu X. α(2A) -AR antagonism by BRL-44408 maleate attenuates acute lung injury in rats with downregulation of ERK1/2, p38MAPK, and p65 pathway. J Cell Physiol. 2020;235:6905–14.
Article CAS PubMed Google Scholar
Tu Y, Li X, Fu Y, Chen Y, Fang H, Li Y, et al. Isocorydine ameliorates IL-6 expression in bone marrow-derived macrophages and acute lung injury induced by lipopolysaccharide. Int J Mol Sci. 2023;24:4629.
Article CAS PubMed PubMed Central Google Scholar
Pei X, Zhang Z, Wang N, Huang G, Min X, Yang Y, et al. Onychiol B attenuates lipopolysaccharide-induced inflammation via MAPK/NF-κB pathways and acute lung injury in vivo. Bioorg Chem. 2023;132: 106351.
Article CAS PubMed Google Scholar
Li D, Ren W, Jiang Z, Zhu L. Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury. Mol Med Rep. 2018;18:4399–409.
CAS PubMed PubMed Central Google Scholar
Zhang Q, Li J, Zhong H, Xu Y. The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-κB signal pathway. Mol Med. 2021;27:115.
Article CAS PubMed PubMed Central Google Scholar
Zhang M, Zhang J, Zhu QM, Zhao WY, Lv X, Yi J, et al. Inula japonica ameliorated the inflammation and oxidative stress in LPS-induced acute lung injury through the MAPK/NF-κB and Keap1/Nrf2 signalling pathways. J Pharm Pharmacol. 2023;75:287–99.
Article PubMed Google Scholar
Xue M, Sun Z, Shao M, Yin J, Deng Z, Zhang J, et al. Diagnostic and prognostic utility of tissue factor for severe sepsis and sepsis-induced acute lung injury. J Transl Med. 2015;13:172.
Article PubMed PubMed Central Google Scholar
Steffel J, Hermann M, Greutert H, Gay S, Luscher TF, Ruschitzka F, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation. 2005;111:1685–9.
Article CAS PubMed Google Scholar
Chen Y, Wang J, Yao Y, Yuan W, Kong M, Lin Y, et al. CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS Lett. 2009;583:2811–8.
Article CAS PubMed Google Scholar
Lu Q, Yu S, Meng X, Shi M, Huang S, Li J, et al. MicroRNAs: important regulatory molecules in acute lung injury/acute respiratory distress syndrome. Int J Mol Sci. 2022;23:5545.
Article CAS PubMed PubMed Central Google Scholar
Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis. 2010;4:19–34.
Article PubMed Google Scholar
Zhong WJ, Liu T, Yang HH, Duan JX, Yang JT, Guan XX, et al. TREM-1 governs NLRP3 inflammasome activation of macrophages by firing up glycolysis in acute lung injury. Int J Biol Sci. 2023;19:242–57.
Article CAS PubMed PubMed Central Google Scholar
Xin Y, Zou L, Lang S. 4-Octyl itaconate (4-OI) attenuates lipopolysaccharide-induced acute lung injury by suppressing PI3K/Akt/NF-κB signaling pathways in mice. Exp Ther Med. 2021;21:141.
Article CAS PubMed Google Scholar
Wang K, Zhang Y, Cao Y, Shi Z, Lin Y, Chen Y, et al. Glycyrrhetinic acid alleviates acute lung injury by PI3K/AKT suppressing macrophagic Nlrp3 inflammasome activation. Biochem Biophys Res Commun. 2020;532:555–62.
Article CAS PubMed Google Scholar
Chen H, Li N, Zhan X, Zheng T, Huang X, Chen Q, et al. Capsaicin protects against lipopolysaccharide-induced acute lung injury through the HMGB1/NF-κB and PI3K/AKT/mTOR pathways. J Inflamm Res. 2021;14:5291–304.
Article CAS PubMed PubMed Central Google Scholar
Xu H, Xu S, Li L, Wu Y, Mai S, Xie Y, et al. Integrated metabolomics, network pharmacology and biological verification to reveal the mechanisms of Nauclea officinalis treatment of LPS-induced acute lung injury. Chin Med. 2022;17:131.
Article CAS PubMed PubMed Central Google Scholar
Zhong R, Xia T, Wang Y, Ding Z, Li W, Chen Y, et al. Physalin B ameliorates inflammatory responses in lipopolysaccharide-induced acute lung injury mice by inhibiting NF-κB and NLRP3 via the activation of the PI3K/Akt pathway. J Ethnopharmacol. 2022;284: 114777.
Article CAS PubMed Google Scholar
Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008;454:455–62.
Article CAS PubMed PubMed Central Google Scholar
Youssef NS, Elzaitony AS, Abdel Baky NA. Diacerein attenuate LPS-induced acute lung injury via inhibiting ER stress and apoptosis: impact on the crosstalk between SphK1/S1P, TLR4/NFκB/STAT3, and NLRP3/IL-1β signaling pathways. Life Sci. 2022;308: 120915.
Article CAS PubMed Google Scholar
Khan MM, Yang WL, Brenner M, Bolognese AC, Wang P. Cold-inducible RNA-binding protein (CIRP) causes sepsis-associated acute lung injury via induction of endoplasmic reticulum stress. Sci Rep. 2017;7:41363.
Article CAS PubMed PubMed Central Google Scholar
Zeng M, Sang W, Chen S, Chen R, Zhang H, Xue F, et al. 4-PBA inhibits LPS-induced inflammation through regulating ER stress and autophagy in acute lung injury models. Toxicol Lett. 2017;271:26–37.
Article CAS PubMed Google Scholar
So JS. Roles of endoplasmic reticulum stress in immune responses. Mol Cells. 2018;41:705–16.
CAS PubMed PubMed Central Google Scholar
Ye L, Zeng Q, Dai H, Zhang W, Wang X, Ma R, et al. Endoplasmic reticulum stress is involved in ventilator-induced lung injury in mice via the IRE1α-TRAF2-NF-κB pathway. Int Immunopharmacol. 2020;78: 106069.
Article CAS PubMed Google Scholar
Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease. Int J Mol Sci. 2018;19:2460.
Article PubMed PubMed Central Google Scholar
Zhang Z, Zhou J, Verma V, Liu X, Wu M, Yu J, et al. Crossed pathways for radiation-induced and immunotherapy-related lung injury. Front Immunol. 2021;12: 774807.
Article CAS PubMed PubMed Central Google Scholar
Liu Z, Chen M, Sun Y, Li X, Cao L, Ma X. Transforming growth factor-β receptor type 2 is required for heparin-binding protein-induced acute lung injury and vascular leakage for transforming growth factor-β/Smad/Rho signaling pathway activation. FASEB J. 2022;36: e22580.
Article CAS PubMed Google Scholar
Du S, Li H, Cui Y, Yang L, Wu J, Huang H, et al. Houttuynia cordata inhibits lipopolysaccharide-induced rapid pulmonary fibrosis by up-regulating IFN-γ and inhibiting the TGF-β1/Smad pathway. Int Immunopharmacol. 2012;13:331–40.
Article CAS PubMed PubMed Central Google Scholar
Shenkar R, Coulson WF, Abraham E. Anti-transforming growth factor-beta monoclonal antibodies prevent lung injury in hemorrhaged mice. Am J Respir Cell Mol Biol. 1994;11:351–7.
Article CAS PubMed Google Scholar
Zhu HP, Huang HY, Wu DM, Dong N, Dong L, Chen CS, et al. Regulatory mechanism of NOV/CCN3 in the inflammation and apoptosis of lung epithelial alveolar cells upon lipopolysaccharide stimulation. Mol Med Rep. 2020;21:1872–80.
CAS PubMed Google Scholar
Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell. 2008;31:918–24.
Article CAS PubMed PubMed Central Google Scholar
Pooladanda V, Thatikonda S, Bale S, Pattnaik B, Sigalapalli DK, Bathini NB, et al. Nimbolide protects against endotoxin-induced acute respiratory distress syndrome by inhibiting TNF-α mediated NF-κB and HDAC-3 nuclear translocation. Cell Death Dis. 2019;10:81.
Article PubMed PubMed Central Google Scholar
Cho HY, Morgan DL, Bauer AK, Kleeberger SR. Signal transduction pathways of tumor necrosis factor–mediated lung injury induced by ozone in mice. Am J Respir Crit Care Med. 2007;175:829–39.
Article CAS PubMed PubMed Central Google Scholar
Yu S, Xie J, Xiang Y, Dai S, Yu D, Sun H, et al. Downregulation of TNF-α/TNF-R1 signals by AT-lipoxin A4 may be a significant mechanism of attenuation in SAP-associated lung injury. Mediators Inflamm. 2019;2019:9019404.
Article PubMed PubMed Central Google Scholar
Gusarova GA, Das SR, Islam MN, Westphalen K, Jin G, Shmarakov IO, et al. Actin fence therapy with exogenous V12Rac1 protects against acute lung injury. JCI Insight. 2021;6: e135753.
Article PubMed PubMed Central Google Scholar
Sauler M, Bazan IS, Lee PJ. Cell death in the lung: the apoptosis-necroptosis axis. Annu Rev Physiol. 2019;81:375–402.
Article CAS PubMed Google Scholar
Albertine KH, Soulier MF, Wang Z, Ishizaka A, Hashimoto S, Zimmerman GA, et al. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol. 2002;161:1783–96.
Article CAS PubMed PubMed Central Google Scholar
Matute-Bello G, Liles WC, Steinberg KP, Kiener PA, Mongovin S, Chi EY, et al. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). J Immunol. 1999;163:2217–25.
Article CAS PubMed Google Scholar
Kitamura Y, Hashimoto S, Mizuta N, Kobayashi A, Kooguchi K, Fujiwara I, et al. Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice. Am J Respir Crit Care Med. 2001;163:762–9.
Article CAS PubMed Google Scholar
Matute-Bello G, Winn RK, Jonas M, Chi EY, Martin TR, Liles WC. Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation. Am J Pathol. 2001;158:153–61.
Article CAS PubMed PubMed Central Google Scholar
Matute-Bello G, Winn RK, Martin TR, Liles WC. Sustained lipopolysaccharide-induced lung inflammation in mice is attenuated by functional deficiency of the Fas/Fas ligand system. Clin Diagn Lab Immunol. 2004;11:358–61.
CAS PubMed PubMed Central Google Scholar
Hamacher J, Lucas R, Lijnen HR, Buschke S, Dunant Y, Wendel A, et al. Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002;166:651–6.
Article PubMed Google Scholar
Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF. Intratracheal instillation of lipopolysaccharide in mice induces apoptosis in bronchial epithelial cells: no role for tumor necrosis factor-alpha and infiltrating neutrophils. Am J Respir Cell Mol Biol. 2001;24:569–76.
Article CAS PubMed Google Scholar
Sun R, Jiang K, Zeng C, Zhu R, Chu H, Liu H, et al. Synergism of TNF-α and IFN-β triggers human airway epithelial cells death by apoptosis and pyroptosis. Mol Immunol. 2023;153:160–9.
Article CAS PubMed Google Scholar
Herold S, Steinmueller M, von Wulffen W, Cakarova L, Pinto R, Pleschka S, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med. 2008;205:3065–77.
Article CAS PubMed PubMed Central Google Scholar
Hogner K, Wolff T, Pleschka S, Plog S, Gruber AD, Kalinke U, et al. Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog. 2013;9: e1003188.
Article PubMed PubMed Central Google Scholar
Ginzberg HH, Shannon PT, Suzuki T, Hong O, Vachon E, Moraes T, et al. Leukocyte elastase induces epithelial apoptosis: role of mitochondial permeability changes and Akt. Am J Physiol Gastrointest Liver Physiol. 2004;287:G286–98.
Article CAS PubMed Google Scholar
Hou L, Zhang J, Liu Y, Fang H, Liao L, Wang Z, et al. MitoQ alleviates LPS-mediated acute lung injury through regulating Nrf2/Drp1 pathway. Free Radic Biol Med. 2021;165:219–28.
Article CAS PubMed Google Scholar
Zhao G, Cao K, Xu C, Sun A, Lu W, Zheng Y, et al. Crosstalk between mitochondrial fission and oxidative stress in paraquat-induced apoptosis in mouse alveolar type II cells. Int J Biol Sci. 2017;13:888–900.
Article CAS PubMed PubMed Central Google Scholar
Fukumoto J, Cox R Jr, Fukumoto I, Cho Y, Parthasarathy PT, Galam L, et al. Deletion of ASK1 protects against hyperoxia-induced acute lung injury. PLoS ONE. 2016;11: e0147652.
Article PubMed PubMed Central Google Scholar
Makena PS, Gorantla VK, Ghosh MC, Bezawada L, Kandasamy K, Balazs L, et al. Deletion of apoptosis signal-regulating kinase-1 prevents ventilator-induced lung injury in mice. Am J Respir Cell Mol Biol. 2012;46:461–9.
Article CAS PubMed PubMed Central Google Scholar
Machino T, Hashimoto S, Maruoka S, Gon Y, Hayashi S, Mizumura K, et al. Apoptosis signal-regulating kinase 1-mediated signaling pathway regulates hydrogen peroxide-induced apoptosis in human pulmonary vascular endothelial cells. Crit Care Med. 2003;31:2776–81.
Article CAS PubMed Google Scholar
Roberts JR, Perkins GD, Fujisawa T, Pettigrew KA, Gao F, Ahmed A, et al. Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit Care Med. 2007;35:2164–70.
Article CAS PubMed Google Scholar
Lin J, Li J, Shu M, Wu W, Zhang W, Dou Q, et al. The rCC16 protein protects against LPS-induced cell apoptosis and inflammatory responses in human lung pneumocytes. Front Pharmacol. 2020;11:1060.
Article CAS PubMed PubMed Central Google Scholar
Mura M, Han B, Andrade CF, Seth R, Hwang D, Waddell TK, et al. The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival. Crit Care. 2006;10:R130.
Article PubMed PubMed Central Google Scholar
Grootjans S, Vanden Berghe T, Vandenabeele P. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ. 2017;24:1184–95.
Article CAS PubMed PubMed Central Google Scholar
Faust H, Mangalmurti NS. Collateral damage: necroptosis in the development of lung injury. Am J Physiol Lung Cell Mol Physiol. 2020;318:L215–25.
Article CAS PubMed Google Scholar
Dong L, Liang F, Lou Z, Li Y, Li J, Chen Y, et al. Necrostatin-1 alleviates lung ischemia-reperfusion injury via inhibiting necroptosis and apoptosis of lung epithelial cells. Cells. 2022;11:3139.
Article CAS PubMed PubMed Central Google Scholar
Yang HH, Jiang HL, Tao JH, Zhang CY, Xiong JB, Yang JT, et al. Mitochondrial citrate accumulation drives alveolar epithelial cell necroptosis in lipopolysaccharide-induced acute lung injury. Exp Mol Med. 2022;54:2077–91.
Article CAS PubMed PubMed Central Google Scholar
Jiang HL, Yang HH, Liu YB, Zhang CY, Zhong WJ, Guan XX, et al. L-OPA1 deficiency aggravates necroptosis of alveolar epithelial cells through impairing mitochondrial function during acute lung injury in mice. J Cell Physiol. 2022;237:3030–43.
Article CAS PubMed Google Scholar
Gong T, Zhang X, Peng Z, Ye Y, Liu R, Yang Y, et al. Macrophage-derived exosomal aminopeptidase N aggravates sepsis-induced acute lung injury by regulating necroptosis of lung epithelial cell. Commun Biol. 2022;5:543.
Article CAS PubMed PubMed Central Google Scholar
Siempos II, Ma KC, Imamura M, Baron RM, Fredenburgh LE, Huh JW, et al. RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury. JCI Insight. 2018;3: e97102.
Article PubMed PubMed Central Google Scholar
Price DR, Benedetti E, Hoffman KL, Gomez-Escobar L, Alvarez-Mulett S, Capili A, et al. Angiopoietin 2 is associated with vascular necroptosis induction in coronavirus disease 2019 acute respiratory distress syndrome. Am J Pathol. 2022;192:1001–15.
Article CAS PubMed PubMed Central Google Scholar
Dong W, He B, Qian H, Liu Q, Wang D, Li J, et al. RAB26-dependent autophagy protects adherens junctional integrity in acute lung injury. Autophagy. 2018;14:1677–92.
Article CAS PubMed PubMed Central Google Scholar
Sun Y, Li C, Shu Y, Ju X, Zou Z, Wang H, et al. Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection. Sci Signal. 2012;5:ra16.
Article PubMed Google Scholar
Li S, Guo L, Qian P, Zhao Y, Liu A, Ji F, et al. Lipopolysaccharide induces autophagic cell death through the PERK-dependent branch of the unfolded protein response in human alveolar epithelial A549 cells. Cell Physiol Biochem. 2015;36:2403–17.
Article CAS PubMed Google Scholar
Ji Q, Sun Z, Yang Z, Zhang W, Ren Y, Chen W, et al. Protective effect of ginsenoside Rg1 on LPS-induced apoptosis of lung epithelial cells. Mol Immunol. 2021;136:168–74.
Article CAS PubMed Google Scholar
Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7:99–109.
Article CAS PubMed PubMed Central Google Scholar
Liu B, He R, Zhang L, Hao B, Jiang W, Wang W, et al. Inflammatory caspases drive pyroptosis in acute lung injury. Front Pharmacol. 2021;12: 631256.
Article CAS PubMed PubMed Central Google Scholar
Guo Y, Zhang H, Lv Z, Du Y, Li D, Fang H, et al. Up-regulated CD38 by daphnetin alleviates lipopolysaccharide-induced lung injury via inhibiting MAPK/NF-κB/NLRP3 pathway. Cell Commun Signal. 2023;21:66.
Article CAS PubMed PubMed Central Google Scholar
Shi X, Li T, Liu Y, Yin L, Xiao L, Fu L, et al. HSF1 protects sepsis-induced acute lung injury by inhibiting NLRP3 inflammasome activation. Front Immunol. 2022;13: 781003.
Article CAS PubMed PubMed Central Google Scholar
Zhang ML, Wang M, Chen J, Liu YJ, Yu YJ, Liu LM, et al. Isopropyl 3-(3, 4-dihydroxyphenyl)-2-hydroxypropanoate protects lipopolysaccharide-induced acute lung injury in mice by attenuating pyroptosis. Eur J Pharmacol. 2023;942: 175545.
Article CAS PubMed Google Scholar
Cong X, Kong W. Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease. Cell Signal. 2020;66: 109485.
Article CAS PubMed Google Scholar
Xiong S, Hong Z, Huang LS, Tsukasaki Y, Nepal S, Di A, et al. IL-1β suppression of VE-cadherin transcription underlies sepsis-induced inflammatory lung injury. J Clin Invest. 2020;130:3684–98.
Article CAS PubMed PubMed Central Google Scholar
Wang Y, Xue L, Wu Y, Zhang J, Dai Y, Li F, et al. Ruscogenin attenuates sepsis-induced acute lung injury and pulmonary endothelial barrier dysfunction via TLR4/Src/p120-catenin/VE-cadherin signalling pathway. J Pharm Pharmacol. 2021;73:893–900.
Article PubMed Google Scholar
Zhao MJ, Jiang HR, Sun JW, Wang ZA, Hu B, Zhu CR, et al. Roles of RAGE/ROCK1 pathway in HMGB1-induced early changes in barrier permeability of human pulmonary microvascular endothelial cell. Front Immunol. 2021;12: 697071.
Article CAS PubMed PubMed Central Google Scholar
Kellner M, Noonepalle S, Lu Q, Srivastava A, Zemskov E, Black SM. ROS signaling in the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Adv Exp Med Biol. 2017;967:105–37.
Article CAS PubMed PubMed Central Google Scholar
Wang L, Dudek SM. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res. 2009;77:39–45.
Article CAS PubMed Google Scholar
Yang CY, Chen CS, Yiang GT, Cheng YL, Yong SB, Wu MY, et al. New insights into the immune molecular regulation of the pathogenesis of acute respiratory distress syndrome. Int J Mol Sci. 2018;19:588.
Article PubMed PubMed Central Google Scholar
Goeckeler ZM, Wysolmerski RB. Myosin phosphatase and cofilin mediate cAMP/cAMP-dependent protein kinase-induced decline in endothelial cell isometric tension and myosin II regulatory light chain phosphorylation. J Biol Chem. 2005;280:33083–95.
Article CAS PubMed Google Scholar
Zhang X, Ye L, Tang W, Ji Y, Zheng L, Chen Y, et al. Wnt/β-catenin participates in the repair of acute respiratory distress syndrome-associated early pulmonary fibrosis via mesenchymal stem cell microvesicles. Drug Des Devel Ther. 2022;16:237–47.
Article CAS PubMed PubMed Central Google Scholar
Villar J, Cabrera-Benitez NE, Ramos-Nuez A, Flores C, Garcia-Hernandez S, Valladares F, et al. Early activation of pro-fibrotic WNT5A in sepsis-induced acute lung injury. Crit Care. 2014;18:568.
Article PubMed PubMed Central Google Scholar
Cabrera-Benitez NE, Parotto M, Post M, Han B, Spieth PM, Cheng WE, et al. Mechanical stress induces lung fibrosis by epithelial-mesenchymal transition. Crit Care Med. 2012;40:510–7.
Article PubMed PubMed Central Google Scholar
Dada LA, Welch LC, Magnani ND, Ren Z, Han H, Brazee PL, et al. Hypercapnia alters stroma-derived Wnt production to limit β-catenin signaling and proliferation in AT2 cells. JCI Insight. 2023;8: e159331.
Article PubMed PubMed Central Google Scholar
Sack KD, Kellum JA, Parikh SM. The angiopoietin-Tie2 pathway in critical illness. Crit Care Clin. 2020;36:201–16.
Article PubMed PubMed Central Google Scholar
Wettschureck N, Strilic B, Offermanns S. Passing the vascular barrier: endothelial signaling processes controlling extravasation. Physiol Rev. 2019;99:1467–525.
Article CAS PubMed Google Scholar
David S, Ghosh CC, Mukherjee A, Parikh SM. Angiopoietin-1 requires IQ domain GTPase-activating protein 1 to activate Rac1 and promote endothelial barrier defense. Arterioscler Thromb Vasc Biol. 2011;31:2643–52.
Article CAS PubMed PubMed Central Google Scholar
Hellenthal KEM, Brabenec L, Wagner NM. Regulation and dysregulation of endothelial permeability during systemic inflammation. Cells. 2022;11:1935.
Article CAS PubMed PubMed Central Google Scholar
Li W, Long L, Yang X, Tong Z, Southwood M, King R, et al. Circulating BMP9 protects the pulmonary endothelium during inflammation-induced lung injury in mice. Am J Respir Crit Care Med. 2021;203:1419–30.
Article CAS PubMed PubMed Central Google Scholar
Zhao H, Anand AR, Ganju RK. Slit2-Robo4 pathway modulates lipopolysaccharide-induced endothelial inflammation and its expression is dysregulated during endotoxemia. J Immunol. 2014;192:385–93.
Article CAS PubMed Google Scholar
London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med. 2010;2:23ra19.
Article PubMed PubMed Central Google Scholar
Morita M, Yoneda A, Tokunoh N, Masaki T, Shirakura K, Kinoshita M, et al. Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models. Proc Natl Acad Sci USA. 2023;120: e2213317120.
Article CAS PubMed PubMed Central Google Scholar
Gong H, Rehman J, Tang H, Wary K, Mittal M, Chaturvedi P, et al. HIF2α signaling inhibits adherens junctional disruption in acute lung injury. J Clin Invest. 2015;125:652–64.
Article PubMed PubMed Central Google Scholar
Liu LY, Shan XQ, Zhang FK, Fan XF, Fan JM, Wang YY, et al. YAP activity protects against endotoxemic acute lung injury by activating multiple mechanisms. Int J Mol Med. 2020;46:2235–50.
Article CAS PubMed Google Scholar
Huang J, Zhang R, Zhai K, Li J, Yao M, Wei S, et al. Venovenous extracorporeal membrane oxygenation promotes alveolar epithelial recovery by activating Hippo/YAP signaling after lung injury. J Heart Lung Transplant. 2022;41:1391–400.
Article CAS PubMed Google Scholar
Roux J, Kawakatsu H, Gartland B, Pespeni M, Sheppard D, Matthay MA, et al. Interleukin-1beta decreases expression of the epithelial sodium channel alpha-subunit in alveolar epithelial cells via a p38 MAPK-dependent signaling pathway. J Biol Chem. 2005;280:18579–89.
Article CAS PubMed Google Scholar
Migneault F, Boncoeur E, Morneau F, Pascariu M, Dagenais A, Berthiaume Y. Cycloheximide and lipopolysaccharide downregulate αENaC mRNA via different mechanisms in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2013;305:L747–55.
Article CAS PubMed Google Scholar
Dagenais A, Frechette R, Yamagata Y, Yamagata T, Carmel JF, Clermont ME, et al. Downregulation of ENaC activity and expression by TNF-alpha in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;286:L301–11.
Article CAS PubMed Google Scholar
Hamidi SH, Kadamboor Veethil S, Hamidi SH. Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective. Pharmacol Rep. 2021;73:712–27.
Article CAS PubMed PubMed Central Google Scholar
Deng J, Wang DX, Deng W, Li CY, Tong J, Ma H. Regulation of alveolar fluid clearance and ENaC expression in lung by exogenous angiotensin II. Respir Physiol Neurobiol. 2012;181:53–61.
Article CAS PubMed Google Scholar
Peteranderl C, Morales-Nebreda L, Selvakumar B, Lecuona E, Vadasz I, Morty RE, et al. Macrophage-epithelial paracrine crosstalk inhibits lung edema clearance during influenza infection. J Clin Invest. 2016;126:1566–80.
Article PubMed PubMed Central Google Scholar
Blondonnet R, Audard J, Belville C, Clairefond G, Lutz J, Bouvier D, et al. RAGE inhibition reduces acute lung injury in mice. Sci Rep. 2017;7:7208.
Article PubMed PubMed Central Google Scholar
Magnani ND, Dada LA, Queisser MA, Brazee PL, Welch LC, Anekalla KR, et al. HIF and HOIL-1L-mediated PKCζ degradation stabilizes plasma membrane Na, K-ATPase to protect against hypoxia-induced lung injury. Proc Natl Acad Sci USA. 2017;114:E10178–86.
Article CAS PubMed PubMed Central Google Scholar
Briva A, Vadasz I, Lecuona E, Welch LC, Chen J, Dada LA, et al. High CO2 levels impair alveolar epithelial function independently of pH. PLoS ONE. 2007;2: e1238.
Article PubMed PubMed Central Google Scholar
Vadasz I, Dada LA, Briva A, Trejo HE, Welch LC, Chen J, et al. AMP-activated protein kinase regulates CO2-induced alveolar epithelial dysfunction in rats and human cells by promoting Na, K-ATPase endocytosis. J Clin Invest. 2008;118:752–62.
CAS PubMed PubMed Central Google Scholar
Gwoździńska P, Buchbinder BA, Mayer K, Herold S, Morty RE, Seeger W, et al. Hypercapnia Impairs ENaC cell surface stability by promoting phosphorylation, polyubiquitination and endocytosis of β-ENaC in a human alveolar epithelial cell line. Front Immunol. 2017;8:591.
Article PubMed PubMed Central Google Scholar
Almaça J, Kongsuphol P, Hieke B, Ousingsawat J, Viollet B, Schreiber R, et al. AMPK controls epithelial Na(+) channels through Nedd4-2 and causes an epithelial phenotype when mutated. Pflugers Arch. 2009;458:713–21.
Article PubMed Google Scholar
Fei X, Ziqian Y, Bingwu Y, Min L, Xinmiao X, Zhen M, et al. Aldosterone alleviates lipopolysaccharide-induced acute lung injury by regulating epithelial sodium channel through PI3K/Akt/SGK1 signaling pathway. Mol Cell Probes. 2021;57: 101709.
Article CAS PubMed Google Scholar
Han J, Li H, Bhandari S, Cao F, Wang XY, Tian C, et al. Maresin conjugates in tissue regeneration 1 improves alveolar fluid clearance by up-regulating alveolar ENaC, Na, K-ATPase in lipopolysaccharide-induced acute lung injury. J Cell Mol Med. 2020;24:4736–47.
Article CAS PubMed PubMed Central Google Scholar
Carnesecchi S, Pache JC, Barazzone-Argiroffo C. NOX enzymes: potential target for the treatment of acute lung injury. Cell Mol Life Sci. 2012;69:2373–85.
Article CAS PubMed PubMed Central Google Scholar
Han W, Li H, Cai J, Gleaves LA, Polosukhin VV, Segal BH, et al. NADPH oxidase limits lipopolysaccharide-induced lung inflammation and injury in mice through reduction-oxidation regulation of NF-κB activity. J Immunol. 2013;190:4786–94.
Article CAS PubMed Google Scholar
Zhang WJ, Wei H, Tien YT, Frei B. Genetic ablation of phagocytic NADPH oxidase in mice limits TNFα-induced inflammation in the lungs but not other tissues. Free Radic Biol Med. 2011;50:1517–25.
Article CAS PubMed PubMed Central Google Scholar
Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221–5.
Article CAS PubMed Google Scholar
Zeng Q, Ye L, Ling M, Ma R, Li J, Chen H, et al. TLR4/TRAF6/NOX2 signaling pathway is involved in ventilation-induced lung injury via endoplasmic reticulum stress in murine model. Int Immunopharmacol. 2021;96: 107774.
Article CAS PubMed Google Scholar
Yue Q, Zhang W, Lin S, Zheng T, Hou Y, Zhang Y, et al. Ejiao ameliorates lipopolysaccharide-induced pulmonary inflammation via inhibition of NFκB regulating NLRP3 inflammasome and mitochondrial ROS. Biomed Pharmacother. 2022;152: 113275.
Article CAS PubMed Google Scholar
Cao Z, Qin H, Huang Y, Zhao Y, Chen Z, Hu J, et al. Crosstalk of pyroptosis, ferroptosis, and mitochondrial aldehyde dehydrogenase 2-related mechanisms in sepsis-induced lung injury in a mouse model. Bioengineered. 2022;13:4810–20.
Article CAS PubMed PubMed Central Google Scholar
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.
Article CAS PubMed PubMed Central Google Scholar
Zhan P, Lu X, Li Z, Wang WJ, Peng K, Liang NN, et al. Mitoquinone alleviates bleomycin-induced acute lung injury via inhibiting mitochondrial ROS-dependent pulmonary epithelial ferroptosis. Int Immunopharmacol. 2022;113: 109359.
Article CAS PubMed Google Scholar
Wang W, Xu R, Zhao H, Xiong Y, He P. CircEXOC5 promotes ferroptosis by enhancing ACSL4 mRNA stability via binding to PTBP1 in sepsis-induced acute lung injury. Immunobiology. 2022;227: 152219.
Article CAS PubMed Google Scholar
Li D, Cong Z, Yang C, Zhu X. Inhibition of LPS-induced Nox2 activation by VAS2870 protects alveolar epithelial cells through eliminating ROS and restoring tight junctions. Biochem Biophys Res Commun. 2020;524:575–81.
Article CAS PubMed Google Scholar
Wu F, Szczepaniak WS, Shiva S, Liu H, Wang Y, Wang L, et al. Nox2-dependent glutathionylation of endothelial NOS leads to uncoupled superoxide production and endothelial barrier dysfunction in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2014;307:L987–97.
Article CAS PubMed PubMed Central Google Scholar
Rafikov R, Dimitropoulou C, Aggarwal S, Kangath A, Gross C, Pardo D, et al. Lipopolysaccharide-induced lung injury involves the nitration-mediated activation of RhoA. J Biol Chem. 2014;289:4710–22.
Article CAS PubMed PubMed Central Google Scholar
Jiang J, Huang K, Xu S, Garcia JGN, Wang C, Cai H. Targeting NOX4 alleviates sepsis-induced acute lung injury via attenuation of redox-sensitive activation of CaMKII/ERK1/2/MLCK and endothelial cell barrier dysfunction. Redox Biol. 2020;36: 101638.
Article CAS PubMed PubMed Central Google Scholar
Dada LA, Chandel NS, Ridge KM, Pedemonte C, Bertorello AM, Sznajder JI. Hypoxia-induced endocytosis of Na, K-ATPase in alveolar epithelial cells is mediated by mitochondrial reactive oxygen species and PKC-zeta. J Clin Invest. 2003;111:1057–64.
Article CAS PubMed PubMed Central Google Scholar
Saha S, Buttari B, Panieri E, Profumo E, Saso L. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020;25:5474.
Article CAS PubMed PubMed Central Google Scholar
Chow CW, Abreu MTH, Suzuki T, Downey GP. Oxidative stress and acute lung injury. Am J Respir Cell Mol Biol. 2003;29:427–31.
Article CAS PubMed Google Scholar
Lee J, Jang J, Park SM, Yang SR. An update on the role of Nrf2 in respiratory disease: molecular mechanisms and therapeutic approaches. Int J Mol Sci. 2021;22:8406.
Article CAS PubMed PubMed Central Google Scholar
Shi K, Xiao Y, Dong Y, Wang D, Xie Y, Tu J, et al. Protective effects of atractylodis lancea rhizoma on lipopolysaccharide-induced acute lung injury via TLR4/NF-κB and Keap1/Nrf2 signaling pathways in vitro and in vivo. Int J Mol Sci. 2022;23:16134.
Article CAS PubMed PubMed Central Google Scholar
Guo Y, Liu Y, Zhao S, Xu W, Li Y, Zhao P, et al. Oxidative stress-induced FABP5 S-glutathionylation protects against acute lung injury by suppressing inflammation in macrophages. Nat Commun. 2021;12:7094.
Article CAS PubMed PubMed Central Google Scholar
Cai W, Shen K, Ji P, Jia Y, Han S, Zhang W, et al. The Notch pathway attenuates burn-induced acute lung injury in rats by repressing reactive oxygen species. Burns Trauma. 2022;10:tkac008.
Article PubMed PubMed Central Google Scholar
Jin H, Zhao K, Li J, Xu Z, Liao S, Sun S. Matrine alleviates oxidative stress and ferroptosis in severe acute pancreatitis-induced acute lung injury by activating the UCP2/SIRT3/PGC1α pathway. Int Immunopharmacol. 2023;117: 109981.
Article CAS PubMed Google Scholar
Ai M, Lin S, Zhang M, Wu T, Yang N, Li Y, et al. Cirsilineol attenuates LPS-induced inflammation in both in vivo and in vitro models via inhibiting TLR-4/NFkB/IKK signaling pathway. J Biochem Mol Toxicol. 2021;35: e22799.
Article CAS PubMed Google Scholar
Zhao D, Zhang X, Feng Y, Bian Y, Fu Z, Wu Y, et al. Taurine alleviates LPS-induced acute lung injury by suppressing TLR-4/NF-κB pathway. Adv Exp Med Biol. 2022;1370:63–72.
Article CAS PubMed Google Scholar
Kong D, Wang Z, Tian J, Liu T, Zhou H. Glycyrrhizin inactivates toll-like receptor (TLR) signaling pathway to reduce lipopolysaccharide-induced acute lung injury by inhibiting TLR2. J Cell Physiol. 2019;234:4597–607.
Article CAS PubMed Google Scholar
Sun L, Liu Y, Liu X, Wang R, Gong J, Saferali A, et al. Nano-enabled reposition of proton pump inhibitors for TLR inhibition: toward a new targeted nanotherapy for acute lung injury. Adv Sci (Weinh). 2022;9: e2104051.
Article PubMed Google Scholar
Yang J, Yang J, Huang X, Xiu H, Bai S, Li J, et al. Glibenclamide alleviates LPS-induced acute lung injury through NLRP3 inflammasome signaling pathway. Mediators Inflamm. 2022;2022:8457010.
Article PubMed PubMed Central Google Scholar
Peukert K, Fox M, Schulz S, Feuerborn C, Frede S, Putensen C, et al. Inhibition of caspase-1 with tetracycline ameliorates acute lung injury. Am J Respir Crit Care Med. 2021;204:53–63.
Article CAS PubMed PubMed Central Google Scholar
Hsu CG, Chavez CL, Zhang C, Sowden M, Yan C, Berk BC. The lipid peroxidation product 4-hydroxynonenal inhibits NLRP3 inflammasome activation and macrophage pyroptosis. Cell Death Differ. 2022;29:1790–803.
Article CAS PubMed PubMed Central Google Scholar
Meng L, Li L, Lu S, Li K, Su Z, Wang Y, et al. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways. Mol Immunol. 2018;94:7–17.
Article CAS PubMed Google Scholar
Chen G, Hou Y, Li X, Pan R, Zhao D. Sepsis-induced acute lung injury in young rats is relieved by calycosin through inactivating the HMGB1/MyD88/NF-κB pathway and NLRP3 inflammasome. Int Immunopharmacol. 2021;96: 107623.
Article CAS PubMed Google Scholar
Hu C, Li J, Tan Y, Liu Y, Bai C, Gao J, et al. Tanreqing injection attenuates macrophage activation and the inflammatory response via the lncRNA-SNHG1/HMGB1 axis in lipopolysaccharide-induced acute lung injury. Front Immunol. 2022;13: 820718.
Article CAS PubMed PubMed Central Google Scholar
Jiang Z, Jiang Y, Fan J, Zhang J, Xu G, Fan Y, et al. Inhibition of cGAS ameliorates acute lung injury triggered by zinc oxide nanoparticles. Toxicol Lett. 2023;373:62–75.
Article CAS PubMed Google Scholar
Huang R, Shi Q, Zhang S, Lin H, Han C, Qian X, et al. Inhibition of the cGAS-STING pathway attenuates lung ischemia/reperfusion injury via regulating endoplasmic reticulum stress in alveolar epithelial type II cells of rats. J Inflamm Res. 2022;15:5103–19.
Article CAS PubMed PubMed Central Google Scholar
Zhang Q, Feng A, Zeng M, Zhang B, Shi J, Lv Y, et al. Chrysosplenol D protects mice against LPS-induced acute lung injury by inhibiting oxidative stress, inflammation, and apoptosis via TLR4-MAPKs/NF-κB signaling pathways. Innate Immun. 2021;27:514–24.
Article CAS PubMed PubMed Central Google Scholar
Li G, Jiang X, Liang X, Hou Y, Zang J, Zhu B, et al. BAP31 regulates the expression of ICAM-1/VCAM-1 via MyD88/NF-κB pathway in acute lung injury mice model. Life Sci. 2023;313: 121310.
Article CAS PubMed Google Scholar
Zhu W, Luo W, Han J, Zhang Q, Ji L, Samorodov AV, et al. Schisandrin B protects against LPS-induced inflammatory lung injury by targeting MyD88. Phytomedicine. 2023;108: 154489.
Article CAS PubMed Google Scholar
Zhang J, Wang C, Wang H, Li X, Xu J, Yu K. Loganin alleviates sepsis-induced acute lung injury by regulating macrophage polarization and inhibiting NLRP3 inflammasome activation. Int Immunopharmacol. 2021;95: 107529.
Article CAS PubMed Google Scholar
Abd El-Fattah EE, Saber S, Mourad AAE, El-Ahwany E, Amin NA, Cavalu S, et al. The dynamic interplay between AMPK/NFκB signaling and NLRP3 is a new therapeutic target in inflammation: emerging role of dapagliflozin in overcoming lipopolysaccharide-mediated lung injury. Biomed Pharmacother. 2022;147: 112628.
Article CAS PubMed Google Scholar
Han S, Yuan R, Cui Y, He J, Wang QQ, Zhuo Y, et al. Hederasaponin C alleviates lipopolysaccharide-induced acute lung injury in vivo and in vitro through the PIP2/NF-κB/NLRP3 signaling pathway. Front Immunol. 2022;13: 846384.
Article CAS PubMed PubMed Central Google Scholar
Cui Y, Weng W, Ding Q, Su Q, Wang X. The protective effect of artesunate on LPS-induced acute respiratory distress syndrome through inhibiting NLRP3 inflammasome signaling. Evid Based Complement Alternat Med. 2022;2022:7655033.
Article PubMed PubMed Central Google Scholar
Zhuo Y, Yang L, Li D, Zhang L, Zhang Q, Zhang S, et al. Syringaresinol resisted sepsis-induced acute lung injury by suppressing pyroptosis via the oestrogen receptor-β signalling pathway. Inflammation. 2022;45:824–37.
Article CAS PubMed Google Scholar
Wang Y, Yang W, Zhao X, Zhang R. Experimental study of the protective effect of simvastatin on lung injury in rats with sepsis. Inflammation. 2018;41:104–13.
Article CAS PubMed Google Scholar
Yuan Q, Jiang YW, Fang QH. Improving effect of Sivelestat on lipopolysaccharide-induced lung injury in rats. APMIS. 2014;122:810–7.
Article CAS PubMed Google Scholar
Kido T, Muramatsu K, Yatera K, Asakawa T, Otsubo H, Kubo T, et al. Efficacy of early sivelestat administration on acute lung injury and acute respiratory distress syndrome. Respirology. 2017;22:708–13.
Article PubMed Google Scholar
McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371:1695–703.
Article PubMed Google Scholar
Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6:691–8.
Article CAS PubMed PubMed Central Google Scholar
Jain NK, Tailang M, Jain HK, Chandrasekaran B, Sahoo BM, Subramanian A, et al. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: a review. Front Pharmacol. 2023;14:1135145.
Article CAS PubMed PubMed Central Google Scholar
Rubin R. Baricitinib is first approved COVID-19 immunomodulatory treatment. JAMA. 2022;327:2281.
CAS PubMed Google Scholar
Bringue J, Guillamat-Prats R, Martinez ML, Torrents E, Camprubi-Rimblas M, Blanch L, et al. Methotrexate ameliorates systemic inflammation and septic associated-lung damage in a cecal ligation and puncture septic rat model. Int J Mol Sci. 2021;22:9612.
Article CAS PubMed PubMed Central Google Scholar
Xue H, Li M. Protective effect of pterostilbene on sepsis-induced acute lung injury in a rat model via the JAK2/STAT3 pathway. Ann Transl Med. 2020;8:1452.
Article CAS PubMed PubMed Central Google Scholar
Xu G, Wan H, Yi L, Chen W, Luo Y, Huang Y, et al. Berberine administrated with different routes attenuates inhaled LPS-induced acute respiratory distress syndrome through TLR4/NF-κB and JAK2/STAT3 inhibition. Eur J Pharmacol. 2021;908: 174349.
Article CAS PubMed PubMed Central Google Scholar
Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia. Italy Autoimmun Rev. 2020;19: 102568.
Article CAS PubMed Google Scholar
Guo L, Wu X, Zhao S, Zhang X, Qian G, Li S. Autophagy inhibition protects from alveolar barrier dysfunction in LPS-induced ALI mice by targeting alveolar epithelial cells. Respir Physiol Neurobiol. 2021;283: 103532.
Article CAS PubMed Google Scholar
Liu D, Wang Q, Yuan W, Wang Q. Irigenin attenuates lipopolysaccharide-induced acute lung injury by inactivating the mitogen-activated protein kinase (MAPK) signaling pathway. Hum Exp Toxicol. 2023;42:9603271231155098.
Article PubMed Google Scholar
Zhang Y, Zhang H, Li Y, Wang M, Qian F. β-Caryophyllene attenuates lipopolysaccharide-induced acute lung injury via inhibition of the MAPK signalling pathway. J Pharm Pharmacol. 2021;73:1319–29.
Article PubMed Google Scholar
Christie JD, Vaslef S, Chang PK, May AK, Gunn SR, Yang S, et al. A randomized dose-escalation study of the safety and anti-inflammatory activity of the p38 mitogen-activated protein kinase inhibitor dilmapimod in severe trauma subjects at risk for acute respiratory distress syndrome. Crit Care Med. 2015;43:1859–69.
Article CAS PubMed Google Scholar
Ahmad S, Zaki A, Manda K, Mohan A, Syed MA. Vitamin-D ameliorates sepsis-induced acute lung injury via augmenting miR-149-5p and downregulating ER stress. J Nutr Biochem. 2022;110: 109130.
Article CAS PubMed Google Scholar
Hsieh PC, Peng CK, Liu GT, Kuo CY, Tzeng IS, Wang MC, et al. Aqueous extract of descuraniae semen attenuates lipopolysaccharide-induced inflammation and apoptosis by regulating the proteasomal degradation and IRE1α-dependent unfolded protein response in A549 cells. Front Immunol. 2022;13: 916102.
Article CAS PubMed PubMed Central Google Scholar
National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Ginde AA, Brower RG, Caterino JM, et al. Early high-dose vitamin D(3) for critically ill, vitamin D-deficient patients. N Engl J Med. 2019;381:2529–40.
Article Google Scholar
Du L, Zhang J, Zhang X, Li C, Wang Q, Meng G, et al. Oxypeucedanin relieves LPS-induced acute lung injury by inhibiting the inflammation and maintaining the integrity of the lung air-blood barrier. Aging (Albany NY). 2022;14:6626–41.
Article CAS PubMed Google Scholar
Wang J, Luo L, Zhao X, Xue X, Liao L, Deng Y, et al. Forsythiae Fructuse extracts alleviates LPS-induced acute lung injury in mice by regulating PPAR-γ/RXR-α in lungs and colons. J Ethnopharmacol. 2022;293: 115322.
Article CAS PubMed Google Scholar
Li T, Zhang C, Wei Y, Zhong H, Shan L, Yu P, et al. Andrographolide derivative AL-1 ameliorates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome and lung permeability. Curr Pharm Des. 2022;28:2508–17.
Article CAS PubMed Google Scholar
Yuan Q, Basit A, Liang W, Qu R, Luan Y, Ren C, et al. Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3. Sci Transl Med. 2021;13:eabc2499.
Article CAS PubMed PubMed Central Google Scholar
Ren R, Xu Z, Wang X, Jiang W, Yu P. Verdiperstat attenuates acute lung injury by modulating MPO/mu-calpain/β-catenin signaling. Eur J Pharmacol. 2022;924: 174940.
Article CAS PubMed Google Scholar
Zhang J, Pan Z, Zhou J, Zhang L, Tang J, Gong S, et al. The myosin II inhibitor, blebbistatin, ameliorates pulmonary endothelial barrier dysfunction in acute lung injury induced by LPS via NMMHC IIA/Wnt5a/β-catenin pathway. Toxicol Appl Pharmacol. 2022;450: 116132.
Article CAS PubMed PubMed Central Google Scholar
Zhuang R, Yang X, Cai W, Xu R, Lv L, Sun Y, et al. MCTR3 reduces LPS-induced acute lung injury in mice via the ALX/PINK1 signaling pathway. Int Immunopharmacol. 2021;90: 107142.
Article CAS PubMed Google Scholar
Liu L, Lalaoui N. 25 years of research put RIPK1 in the clinic. Semin Cell Dev Biol. 2021;109:86–95.
Article CAS PubMed Google Scholar
Lin B, Jin Z, Chen X, Zhao L, Weng C, Chen B, et al. Necrostatin-1 protects mice from acute lung injury by suppressing necroptosis and reactive oxygen species. Mol Med Rep. 2020;21:2171–81.
CAS PubMed PubMed Central Google Scholar
Cui YR, Qu F, Zhong WJ, Yang HH, Zeng J, Huang JH, et al. Beneficial effects of aloperine on inflammation and oxidative stress by suppressing necroptosis in lipopolysaccharide-induced acute lung injury mouse model. Phytomedicine. 2022;100: 154074.
Article PubMed Google Scholar
Tamada N, Tojo K, Yazawa T, Goto T. Necrosis rather than apoptosis is the dominant form of alveolar epithelial cell death in lipopolysaccharide-induced experimental acute respiratory distress syndrome model. Shock. 2020;54:128–39.
Article CAS PubMed Google Scholar
Matthay MA, Abraham E. Beta-adrenergic agonist therapy as a potential treatment for acute lung injury. Am J Respir Crit Care Med. 2006;173:254–5.
Article PubMed Google Scholar
Gates S, Perkins GD, Lamb SE, Kelly C, Thickett DR, Young JD, et al. Beta-agonist lung injury trial-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome. Health Technol Assess. 2013;17:v–vi.
Article CAS PubMed PubMed Central Google Scholar
Gao Smith F, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, et al. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet. 2012;379:229–35.
Article PubMed Google Scholar
Festic E, Carr GE, Cartin-Ceba R, Hinds RF, Banner-Goodspeed V, Bansal V, et al. Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome. Crit Care Med. 2017;45:798–805.
Article CAS PubMed PubMed Central Google Scholar
Ahmad AA, Ammar MA, Mohamed MH, Fouad MK. The role of inhaled corticosteroids and B2 agonist in prevention of ARDS in high risk patients admitted to ICU. QJM Int J Med. 2020;113:hcaa039.72.
Google Scholar
Tzotzos S, Fischer B, Fischer H, Pietschmann H, Lucas R, Dupre G, et al. AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulm Pharmacol Ther. 2013;26:356–63.
Article CAS PubMed PubMed Central Google Scholar
Hartmann EK, Boehme S, Duenges B, Bentley A, Klein KU, Kwiecien R, et al. An inhaled tumor necrosis factor-alpha-derived TIP peptide improves the pulmonary function in experimental lung injury. Acta Anaesthesiol Scand. 2013;57:334–41.
Article CAS PubMed Google Scholar
Krenn K, Lucas R, Croize A, Boehme S, Klein KU, Hermann R, et al. Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial. Crit Care. 2017;21:194.
Article PubMed PubMed Central Google Scholar
Wang Q, Yan SF, Hao Y, Jin SW. Specialized pro-resolving mediators regulate alveolar fluid clearance during acute respiratory distress syndrome. Chin Med J (Engl). 2018;131:982–9.
Article CAS PubMed Google Scholar
Yang Q, Xu HR, Xiang SY, Zhang C, Ye Y, Shen CX, et al. Resolvin conjugates in tissue regeneration 1 promote alveolar fluid clearance by activating alveolar epithelial sodium channels and Na, K-ATPase in lipopolysaccharide-induced acute lung injury. J Pharmacol Exp Ther. 2021;379:156–65.
Article CAS PubMed Google Scholar
Niu F, Xu X, Zhang R, Sun L, Gan N, Wang A. Ursodeoxycholic acid stimulates alveolar fluid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J Cell Physiol. 2019;234:20057–65.
Article CAS PubMed Google Scholar
Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322:1261–70.
Article PubMed PubMed Central Google Scholar
Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol. 2020;219: 108544.
Article CAS PubMed PubMed Central Google Scholar
de Alencar JCG, Moreira CL, Muller AD, Chaves CE, Fukuhara MA, da Silva EA, et al. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;72:e736–41.
Article PubMed Google Scholar
De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020;34:13185–93.
Article PubMed Google Scholar
Li J, Lu K, Sun F, Tan S, Zhang X, Sheng W, et al. Panaxydol attenuates ferroptosis against LPS-induced acute lung injury in mice by Keap1-Nrf2/HO-1 pathway. J Transl Med. 2021;19:96.
Article CAS PubMed PubMed Central Google Scholar
Kang JY, Xu MM, Sun Y, Ding ZX, Wei YY, Zhang DW, et al. Melatonin attenuates LPS-induced pyroptosis in acute lung injury by inhibiting NLRP3-GSDMD pathway via activating Nrf2/HO-1 signaling axis. Int Immunopharmacol. 2022;109: 108782.
Article CAS PubMed Google Scholar
Kong L, Deng J, Zhou X, Cai B, Zhang B, Chen X, et al. Sitagliptin activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury. Cell Death Dis. 2021;12:928.
Article CAS PubMed PubMed Central Google Scholar
Sul OJ, Ra SW. Quercetin prevents LPS-induced oxidative stress and inflammation by modulating NOX2/ROS/NF-kB in lung epithelial cells. Molecules. 2021;26:6949.
Article CAS PubMed PubMed Central Google Scholar
Abdelmageed ME, El-Awady MS, Suddek GM. Apocynin ameliorates endotoxin-induced acute lung injury in rats. Int Immunopharmacol. 2016;30:163–70.
Article CAS PubMed Google Scholar
Cui Y, Wang Y, Li G, Ma W, Zhou XS, Wang J, et al. The Nox1/Nox4 inhibitor attenuates acute lung injury induced by ischemia-reperfusion in mice. PLoS ONE. 2018;13: e0209444.
Article CAS PubMed PubMed Central Google Scholar
Rajasekaran S, Pattarayan D, Rajaguru P, Sudhakar Gandhi PS, Thimmulappa RK. MicroRNA regulation of acute lung injury and acute respiratory distress syndrome. J Cell Physiol. 2016;231:2097–106.
Article CAS PubMed Google Scholar
Xu X, Liu X, Dong X, Yang Y, Liu L. MiR-199a-3p-regulated alveolar macrophage-derived secretory autophagosomes exacerbate lipopolysaccharide-induced acute respiratory distress syndrome. Front Cell Infect Microbiol. 2022;12:1061790.
Article CAS PubMed PubMed Central Google Scholar
Yang Y, Yang F, Yu X, Wang B, Yang Y, Zhou X, et al. miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury. Biomed Pharmacother. 2019;112: 108664.
Article CAS PubMed Google Scholar
Huang H, Zhu J, Gu L, Hu J, Feng X, Huang W, et al. TLR7 mediates acute respiratory distress syndrome in sepsis by sensing extracellular miR-146a. Am J Respir Cell Mol Biol. 2022;67:375–88.
Article CAS PubMed PubMed Central Google Scholar
Saba R, Sorensen DL, Booth SA. MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front Immunol. 2014;5:578.
Article PubMed PubMed Central Google Scholar
Liu F, Peng W, Chen J, Xu Z, Jiang R, Shao Q, et al. Exosomes derived from alveolar epithelial cells promote alveolar macrophage activation mediated by miR-92a-3p in sepsis-induced acute lung injury. Front Cell Infect Microbiol. 2021;11: 646546.
Article CAS PubMed PubMed Central Google Scholar
Wang L, Yuan N, Li Y, Ma Q, Zhou Y, Qiao Z, et al. Stellate ganglion block relieves acute lung injury induced by severe acute pancreatitis via the miR-155-5p/SOCS5/JAK2/STAT3 axis. Eur J Med Res. 2022;27:231.
Article CAS PubMed PubMed Central Google Scholar
Li G, Wang B, Ding X, Zhang X, Tang J, Lin H. Plasma extracellular vesicle delivery of miR-210-3p by targeting ATG7 to promote sepsis-induced acute lung injury by regulating autophagy and activating inflammation. Exp Mol Med. 2021;53:1180–91.
Article CAS PubMed PubMed Central Google Scholar
Yang Y, Li L. Depleting microRNA-146a-3p attenuates lipopolysaccharide-induced acute lung injury via up-regulating SIRT1 and mediating NF-κB pathway. J Drug Target. 2021;29:420–9.
Article CAS PubMed Google Scholar
Liu B, Chen F, Cheng NT, Tang Z, Wang XG, Xu M. MicroRNA-1224-5p aggravates sepsis-related acute lung injury in mice. Oxid Med Cell Longev. 2022;2022:9493710.
PubMed PubMed Central Google Scholar
Chen YF, Hu F, Wang XG, Tang Z, Tang HX, Xu M. MicroRNA-23a-5p is involved in the regulation of lipopolysaccharide-induced acute lung injury by targeting HSP20/ASK1. Oxid Med Cell Longev. 2021;2021:9942557.
PubMed PubMed Central Google Scholar
Wang C, Chen Y, Cheng NT, Yang ZT, Tang HX, Xu M. MicroRNA-762 modulates lipopolysaccharide-induced acute lung injury via SIRT7. Immunol Invest. 2022;51:1407–22.
Article CAS PubMed Google Scholar
Jiao Y, Zhang T, Zhang C, Ji H, Tong X, Xia R, et al. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. Crit Care. 2021;25:356.
Article PubMed PubMed Central Google Scholar
Yang J, Do-Umehara HC, Zhang Q, Wang H, Hou C, Dong H, et al. miR-221-5p-mediated downregulation of JNK2 aggravates acute lung injury. Front Immunol. 2021;12: 700933.
Article CAS PubMed PubMed Central Google Scholar
Gao W, Zhang Y. Depression of lncRNA MINCR antagonizes LPS-evoked acute injury and inflammatory response via miR-146b-5p and the TRAF6-NFkB signaling. Mol Med. 2021;27:124.
Article CAS PubMed PubMed Central Google Scholar
Gong X, Zhu L, Liu J, Li C, Xu Z, Liu J, et al. MIR3142HG promotes lipopolysaccharide-induced acute lung injury by regulating miR-450b-5p/HMGB1 axis. Mol Cell Biochem. 2021;476:4205–15.
Article CAS PubMed Google Scholar
Gao Y, Li S, Dong R, Li X. Long noncoding RNA MIR3142HG accelerates lipopolysaccharide-induced acute lung injury via miR-95-5p/JAK2 axis. Hum Cell. 2022;35:856–70.
Article CAS PubMed Google Scholar
Kong F, Sun Y, Song W, Zhou Y, Zhu S. MiR-216a alleviates LPS-induced acute lung injury via regulating JAK2/STAT3 and NF-κB signaling. Hum Cell. 2020;33:67–78.
Article CAS PubMed Google Scholar
He B, Zhou W, Rui Y, Liu L, Chen B, Su X. MicroRNA-574-5p attenuates acute respiratory distress syndrome by targeting HMGB1. Am J Respir Cell Mol Biol. 2021;64:196–207.
Article CAS PubMed PubMed Central Google Scholar
Huang Z, Huang H, Shen M, Li C, Liu C, Zhu H, et al. MicroRNA-155-5p modulates the progression of acute respiratory distress syndrome by targeting interleukin receptors. Bioengineered. 2022;13:11732–41.
Article CAS PubMed PubMed Central Google Scholar
Luo D, Dai W, Feng X, Ding C, Shao Q, Xiao R, et al. Suppression of lncRNA NLRP3 inhibits NLRP3-triggered inflammatory responses in early acute lung injury. Cell Death Dis. 2021;12:898.
Article CAS PubMed PubMed Central Google Scholar
Zhao Y, Zheng H, Yang S, Zhang X, Dong W, Shi Y, et al. Catechin regulates miR-182/GGPPS1 signaling pathway and inhibits LPS-induced acute lung injury in mice. Immunopharmacol Immunotoxicol. 2022;44:58–66.
Article CAS PubMed Google Scholar
Wang H, Wang S, Huang S. MiR-494-3p alleviates acute lung injury through regulating NLRP3 activation by targeting CMPK2. Biochem Cell Biol. 2021;99:286–95.
Article CAS PubMed Google Scholar
Xu J, Xu D, Yu Z, Fu Z, Lv Z, Meng L, et al. Exosomal miR-150 partially attenuated acute lung injury by mediating microvascular endothelial cells and MAPK pathway. Biosci Rep. 2022;42: BSR20203363.
Article CAS PubMed Google Scholar
Lv X, Zhang XY, Zhang Q, Nie YJ, Luo GH, Fan X, et al. lncRNA NEAT1 aggravates sepsis-induced lung injury by regulating the miR-27a/PTEN axis. Lab Invest. 2021;101:1371–81.
Article CAS PubMed Google Scholar
Zhao D, Wang C, Liu X, Liu N, Zhuang S, Zhang Q, et al. CircN4bp1 facilitates sepsis-induced acute respiratory distress syndrome through mediating macrophage polarization via the miR-138-5p/EZH2 axis. Mediators Inflamm. 2021;2021:7858746.
Article PubMed PubMed Central Google Scholar
Wei X, Yi X, Lv H, Sui X, Lu P, Li L, et al. MicroRNA-377-3p released by mesenchymal stem cell exosomes ameliorates lipopolysaccharide-induced acute lung injury by targeting RPTOR to induce autophagy. Cell Death Dis. 2020;11:657.
Article CAS PubMed PubMed Central Google Scholar
Liu C, Xiao K, Xie L. Advances in the regulation of macrophage polarization by mesenchymal stem cells and implications for ALI/ARDS treatment. Front Immunol. 2022;13: 928134.
Article CAS PubMed PubMed Central Google Scholar
Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell. 2020;11:707–22.
Article CAS PubMed PubMed Central Google Scholar
Wu KH, Li JP, Chao WR, Lee YJ, Yang SF, Cheng CC, et al. Immunomodulation via MyD88-NFκB signaling pathway from human umbilical cord-derived mesenchymal stem cells in acute lung injury. Int J Mol Sci. 2022;23:5295.
Article CAS PubMed PubMed Central Google Scholar
Lei L, Guo Y, Lin J, Lin X, He S, Qin Z, et al. Inhibition of endotoxin-induced acute lung injury in rats by bone marrow-derived mesenchymal stem cells: role of Nrf2/HO-1 signal axis in inhibition of NLRP3 activation. Biochem Biophys Res Commun. 2021;551:7–13.
Article CAS PubMed Google Scholar
Li L, Dong L, Zhang J, Gao F, Hui J, Yan J. Mesenchymal stem cells with downregulated Hippo signaling attenuate lung injury in mice with lipopolysaccharide-induced acute respiratory distress syndrome. Int J Mol Med. 2019;43:1241–52.
CAS PubMed Google Scholar
Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39.
Article PubMed PubMed Central Google Scholar
Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3:24–32.
Article PubMed Google Scholar
Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7:154–62.
Article PubMed Google Scholar
Lv H, Chen W, Xiang AP, Zhang Q, Yang Y, Yi H, et al. Mesenchymal stromal cells as a salvage treatment for confirmed acute respiratory distress syndrome: preliminary data from a single-arm study. Intensive Care Med. 2020;46:1944–7.
Article PubMed Google Scholar
Bellingan G, Jacono F, Bannard-Smith J, Brealey D, Meyer N, Thickett D, et al. Primary analysis of a phase 1/2 study to assess MultiStem® cell therapy, a regenerative advanced therapy medicinal product (ATMP), in acute respiratory distress syndrome (MUST-ARDS). In: Bellingan G, editor., et al., B14 Late breaking clinical trials. Dallas: American Thoracic Society; 2019. p. A7353.
Chapter Google Scholar
Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering (Beijing). 2020;6:1153–61.
CAS PubMed Google Scholar
Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, et al. Mesenchymal stem cell therapy for severe COVID-19. Signal Transduct Target Ther. 2021;6:339.
Article CAS PubMed PubMed Central Google Scholar
Gorman EA, Rynne J, Gardiner HJ, Rostron AJ, Bannard-Smith J, Bentley AM, et al. Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID Trial): a multicenter, randomized, controlled clinical trial. Am J Respir Crit Care Med. 2023;208:256–69.
Article CAS PubMed Google Scholar
Fernandez-Francos S, Eiro N, Gonzalez-Galiano N, Vizoso FJ. Mesenchymal stem cell-based therapy as an alternative to the treatment of acute respiratory distress syndrome: current evidence and future perspectives. Int J Mol Sci. 2021;22:7850.
Article CAS PubMed PubMed Central Google Scholar
Khan YA, Fan E, Ferguson ND. Precision medicine and heterogeneity of treatment effect in therapies for ARDS. Chest. 2021;160:1729–38.
Article PubMed PubMed Central Google Scholar
Wilson JG, Calfee CS. ARDS subphenotypes: understanding a heterogeneous syndrome. Crit Care. 2020;24:102.
Article PubMed PubMed Central Google Scholar
Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611–20.
Article PubMed PubMed Central Google Scholar
Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax. 2018;73:439–45.
Article PubMed Google Scholar
Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195:331–8.
Article CAS PubMed PubMed Central Google Scholar
Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax. 2017;72:876–83.
Article CAS PubMed Google Scholar
Calfee CS, Janz DR, Bernard GR, May AK, Kangelaris KN, Matthay MA, et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest. 2015;147:1539–48.
Article PubMed Google Scholar
Riva DR, Oliveira MB, Rzezinski AF, Rangel G, Capelozzi VL, Zin WA, et al. Recruitment maneuver in pulmonary and extrapulmonary experimental acute lung injury. Crit Care Med. 2008;36:1900–8.
Article PubMed Google Scholar
Leite-Junior JH, Garcia CS, Souza-Fernandes AB, Silva PL, Ornellas DS, Larangeira AP, et al. Methylprednisolone improves lung mechanics and reduces the inflammatory response in pulmonary but not in extrapulmonary mild acute lung injury in mice. Crit Care Med. 2008;36:2621–8.
Article CAS PubMed Google Scholar
Bos LDJ, Scicluna BP, Ong DSY, Cremer O, van der Poll T, Schultz MJ. Understanding heterogeneity in biologic phenotypes of acute respiratory distress syndrome by leukocyte expression profiles. Am J Respir Crit Care Med. 2019;200:42–50.
Article CAS PubMed Google Scholar
Garcia PDW, Caccioppola A, Coppola S, Pozzi T, Ciabattoni A, Cenci S, et al. Latent class analysis to predict intensive care outcomes in acute respiratory distress syndrome: a proposal of two pulmonary phenotypes. Crit Care. 2021;25:154.
Article Google Scholar

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by grants of the China Primary Health Care Foundation (Grant No. YLGX-ZZ-2020001 to S.L.), and the Natural Science Foundation of Hubei Province (Grant No. 2021CFB376, to YB).

Author information

Qianrui Huang and Yue Le are contributed equally to this work.

Authors and Affiliations

Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095, Jie Fang Avenue, Wuhan, 430030, China
Qianrui Huang, Shusheng Li & Yi Bian
Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jie Fang Avenue, Wuhan, 430030, China
Qianrui Huang, Shusheng Li & Yi Bian
Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjia Bridge, Hunan Road, Gu Lou District, Nanjing, 210009, China
Yue Le

Authors

Qianrui Huang
View author publications
You can also search for this author in PubMed Google Scholar
Yue Le
View author publications
You can also search for this author in PubMed Google Scholar
Shusheng Li
View author publications
You can also search for this author in PubMed Google Scholar
Yi Bian
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

SL and YB designed the structure of the article; QH and YL wrote the manuscript; QH and YL created the figures and tables. SL and YB made revisions and proofread the manuscript. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Shusheng Li or Yi Bian.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article

Huang, Q., Le, Y., Li, S. et al. Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS). Respir Res 25, 30 (2024). https://doi.org/10.1186/s12931-024-02678-5

Download citation

Received: 30 September 2023
Accepted: 03 January 2024
Published: 13 January 2024
DOI: https://doi.org/10.1186/s12931-024-02678-5

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Abstract

Similar content being viewed by others

Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome

Mesenchymal Stromal Cell Therapy in Typical ARDS and Severe COVID-19

Acute Respiratory Distress Syndrome: Therapeutics, Pathobiology, and Prognosis

Background

Pathophysiology and pathogenesis of ARDS

Excessive inflammation

Endothelial and epithelial permeability

Alveolar fluid clearance

Oxidative stress and lung injury

Molecular mechanisms and signaling pathways

Signaling pathways related to inflammation

Pattern recognition receptors

NF-κB signaling pathway

Notch signaling pathway

Janus kinase (JAK)/STAT signaling pathway

MAPK signaling pathway

PI3K/AKT signaling pathway

ER stress-mediated signaling pathway

Transforming growth factor-β (TGF-β)/Small mothers against decapentaplegic (Smad) signaling pathway

TNF-α signaling pathway

Increased endothelium and epithelium permeability

Alveolar epithelial and pulmonary endothelial cell death

Intercellular junction impairment of epithelium and endothelium

Impaired alveolar fluid clearance

ROS-mediated signaling pathways

Emerging pharmacologic therapies for ARDS

Pharmacologic therapies for ARDS

Therapeutic agents potentially targeting anti-inflammation

Therapeutic agents potentially protecting the alveolar-capillary barrier

Therapeutic agents potentially enhancing AFC

Therapeutic agents potentially attenuating oxidative injuries

MicroRNAs in ARDS

Mesenchymal stromal cell therapy

Subphenotypes in ARDS and prospects for targeted therapies

Conclusions

Availability of data and materials

Abbreviations

References

Acknowledgements

Funding

Author information

Authors and Affiliations

Contributions

Corresponding authors

Ethics declarations

Ethics approval and consent to participate

Consent for publication

Competing interests

Additional information

Publisher's Note

Rights and permissions

About this article

Cite this article

Share this article

Keywords

Search

Navigation